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PHAR!-11\COLOGIC INVI:STIGATION OF THE ANTI- JNFLN·1MATORY 
ACTIVITY OF CRYOGENINE AND SELECTED 
IJENZOQUINOLIZJ.NE DEHIVATJ.VES 
Abstract of Dissertation 
l:t has become apparent in recent years that many centrally active 
agents possess potential anti-· inflammatory capabilities. The central or 
peripheral mechanisms of action for these agents have not been delirwutcd 
nor has their clinical efficacy been established or refuted. 1be cen-
trally active drugs, cryogeni.ne s.nd tetrabenazine (a benzoquinoli zinc 
derivative), previously have been shol'in in this laboratory to inhibit 
certain models of induced inflammation. The present study in rats veri-
fied the anti-inflammatory properti()S of cryogonine and established that 
a structurally related seri~s of benzoquinolizine derivatives possessed 
the capability of inhibiting hoth exudative (carn\geenin-induced pedal 
ede!na) and proliferative (cotton p•.!llet g1·m~uloma) mo,.iels of inflamm"'.tion 
when administeTed orally. 
11w anti-i.nfl}l.n\mntor_v a\"U.v.ity t'f those Jwn.zoq11inoli.zine derivative<; 
with reserpine-like ?oc:tiv'if:y (t<'trHheniizine, HO 4--l?.B4, ;md b<~nz'lu:in8!nidl") 
~;as associated with but apparently not dependent upon stimulation of the 
pituitary-adrenal a)lj s. There did not nppcax to be .fmy C'.l!'l'elati on of 
sedation, depletion of brain monoamines, or analgesia 1d th the al!ti-
infl.ammatory potency of these compounds. Tho extreme sedation and auto·· 
no.mic side- effects manifc:.ted at effective C?.nti--inf.lannnatory dosage 
levels diminishes their possible utility in clinie.al practice. 
A scc.ond type of benwquinolizine derivativ0 (RO 1-9564) also demon .. 
strat:::d potent anti-inflwnmatory activity. However, this llcbvity was 
not accompanied by depletion of brain amines, sedation, or autonomic 
man] festntions and there was li tt lc to no apparent stimulation of the 
pituitP.ry .. adrenal axis at anti-inflammatory dosage levels. 11H.' lack of 
obvious si.de·-effects for this second type of benzoquinolizine suggests 
that they may be clinically useful anti-inflammatory drugs either alone 
or in combination with mo:re established agents. 
The anti-inflammatory activity of cryogenine was not associated with 
depletion of whole brain or heart i<lOnoamines. At anti--infJ ammatory dosage 
levels, there 1;as 211 apparent stimulation of the pituitary-adTenal axis 
but this may ha.ve been g side-·cffcct rather th<m the mode of action foX' 
this compound. Adrenal stimulation need 110t preclude its utility in 
clinical practice, since aspirin, the most clinically reliable and widely 
used anti-inflammatory compotmd to date, also has been reported to cause 
adrenal stimulation at high dosage levels. 
r 
ACKNOWLEDGEMENTS 
I would like to convey my sincere appreciation to: 
Dr. Marvin H. Malone for his guidance, supporG, and patience 
throughout the course of this investigation. I am deeply 
grateful for his interest in me and for the philosophy he 
has imparted to me over the many years of our association. 
Drs. John K. Brown, Paul H. Gross, Carl C. Riedesel, 
and Donald Y. Shirachi for their interest and helpful sug-
gestions. 
Mr. John Ewan, Miss Paula Finley, Mr. Benny Kwok, 
and r1r. Ric4ard Li for their careful technical assistance. 
Nrs. "Jacqueline Ellert for her cooperation and 
assistance in the necessary surgical procedures. 
Mr. Stanley T .. OrP..aye, i•1r. \r/illiam C. Watson and the 
author's o·ther fello~tl graduate students for their generous 
assistancf3--
The School of Pharmacy for the privilege of using 
their equipment and facilities. 
The Department of Physiology-Pharmacology of the 
School of Pharmacy and the National Institute of Arthritis 
and Netabolic Diseases for their financial support oyer the 
past i'our years. 
iii 
I 
-' 
Table 
I. 
II. 
III. 
IV. 
v .. 
VL. 
VII. 
VIII. 
DC .. 
LIST OF TABLES 
Effect of intraperitoneally administered 
reserpine acetate and tetrabenazine acetate 
upon tissue amine (5HT = serotonin; NE = 
norepinephrine) levels expressed as mcg/g 
wet weight • • • • • • • • • • • • • • • • 
Effect of intraperitoneally administered 
cryogenine acetate upon tissue amine levels 
expressed as mcg/g wet weight- • • • • • • • 
Effect of intraperitoneally administered 
cryogenine acetate upon tissue amine levels 
expressed as mcg/g wet \'!eight • • • • • • • 
Effect of intraperitoneal control injections 
o.f acetic acid upon tissue amine levels 
expressed as mcg/g wet weight • • • • ~ • • 
Effect of f'ood dt=Jpri vat ion a11d dehydration 
Page 
• • 31 
• • 33 
• • 36 
• • 38 
u.pon cotton pellet granuloma formation • .. .. .. 40 
Effect o.f orally administered hydrocortisone· . 
upon cotton pnllet granuloma formation • • • • 43 
Effect of orally administered indomethacin_ 
upon cotton pellet granuloma formation .. • 
Effect of orally administered phenylbutazone 
upon cotton pellet granuloma, formation .. • 
Effect of orally administered GOdium 
phenobarbital upon cotton pellet granuloma 
formation • • • • • • .. • • • .. • . .. • • .. • 
• • 45 
47 
.. .. 50 
X. Effect of orally administered chlorpromazj_ne 
hydrochloride upon cotton pellet granuloma 
XI. 
XII. 
formation • .. • .. • .. • • • .. • • .. • a • • • • 52 
Effect of orally administered reserpine upon 
cotton pellet granuloma formation • • • .. ... 
Effect of- orally administered tetrabenazine 
upon cotton pellet rsranuloma formation ,. • 
• • 
• • 
54 
57 
XIII.. 'Effect of orally administe:r.~ed RO L~-128'+ upon 
cotton pellet granuloma formation • ., • ~ .. • • 60 
iv 
;----~-_-. ------- ------------
Table 
XIV. Effect of orally administered benzquinamide 
upon cotton pellet granuloma formation • • 
XV. Effect of orally administered RO 1-9564 upon 
v 
Page 
• • 
62 
cotton pellet granuloma formation • • • • • • • 65 
XVI. Effect of orally administered cryogenine upon 
cotton pellet granuloma formation "' • •· • • • • 6? 
XVII. 
XVIII. 
Effect of orally administered tetrabenazine 
upon carrageenin-induced pedal edema .. • • 
Effect of orally ad.ministered HO l~-1284 upon 
carrageenin-:i.l"J.dUGed pedal edema e • ., o • ., 
• • 
. .. 
XIX. Effect of orally administered benzquinamide .. 
72 
upon carrageenin--induced pedal edema • • • • • ?6 
XX., Effect of orally administered RO 1·-9564 upon 
carrageenin-induced pedal edema • • • • • • • • ?8 
XXI. Effect of orally administered cryogenine upon 
carrageenin-incl.uced pedal edema in intact and 
adrenalectomized rats ............... ., ., so· 
Figure 
1. 
2. 
LIST OF FIGURES 
Sti"llctures of: 
Cryogenino 
Benzoquinolizirie derivatives 
Fluorescent spectra of: 
Serotonin standard (1.5 meg) 
Extracted serotonin (1.5 meg) 
pooled brain homogenate 
Reagent blank • • • • • • • • 
Fluorescent spectra of: 
• • • • • • • 
added to 
• • • • • • • 
ad.ded 
Norepinephrine standard (1.0 meg) 
Extracted norepinephrine (L.O meg) 
to pooled brain homogenate 
Reagent blank • • • • • • • • • • 0 .. • • • 
4. ·standard curves of exogenous amine added to 
Page 
11 
24 
26 
and extracted from a pooled brain homogenate • 29 
5.. Varia::;ion with i;ime of pE:dal edema inclueed by 
snbplanta:r· injection of' 0.1 ml of 1% aqueous 
carrageenin • • • • • • • • • ~ • • • • • • • 
vi 
69 
r 
INTRODUCTION 
To date, inflammatory disease remains.one of the 
major medical problems in.the world .. It has been estimated 
that one out of sixteen Americans is afflicted \'lith some 
form of .rheumatic disease (1). Such (liseases st'rike all 
• o.. -- .... J - "". .. .. .. 41 .. I • "' age groups wn;n :::;u;o or· persons casao.Lea. oy rneuma1;o1C1 
arthritis being under 45 years of age. While generally 
not acutely lethal, the rheumatic disorders cause more 
disability than all accidents combined and_ rank second 
only to nervous and mental disorders (2). In 1965, it was 
estimated that about 3,300,000 people have some limitation 
o.f activity clue to osteo- and rhematoid-·arthritis --
697,000 B.re unable to carry out their major activity? 
1,880,000 are limited in their major activity, and 714,000 
are limited but not in their rriajor activity (3). It should 
be noted that the previous statistics apply to only the 
above inflammatory diseases and do not account for losses 
and disability due to the many other acute and chronic 
inflammatory disorders. 
Inflammation is a complex and dynamic process which 
consists of many interdependent cellular and biochemical 
events. The process is aimed at neutralizing the effects 
of noxious stimuli and effecting tissue repair in areas 
damaged by those stimuli. Therefore, it may be considered 
a homeostatic mechanism. Similar to other biological 
1 
regulatory mechanisms, the inflammatory process is 
susceptible to overcompensation (i.e. loss of control). 
When the inflammatory reaction becomes excessive inrela-
tion to its stimulus, it can cause more harm than the 
original injury. There are many diverse stimuli which 
may initiate the inflammatory process in any area of the 
body. In spite of the fact that there is this great 
diversi·l:;y in the causes and locations of inflammation, 
the process always seems to follow a rather orderly mor-
phological and biochemical sequence (4). The differences 
bet;,.ieen the various inflammatory states are generally 
quantitative rather than qualitative in nature. 
2 
The first noticeable effects caused by a noxious 
stimuluB are upon the microcirculation. The earliest event 
is uGually a transierri; a1:teriola.x· vasoconstriction (5), 
.foll·o\.,red by a biphasic vasodilation after a few seconds 
(6)<» '.flhis secondary phase (up to ten minutes in dur.~t:Lon) 
is characterized by increased capillary permeability and 
extravasation of plasma proteins into the injured site 
causing ed.emB... As the tertia.ry phase is initiated (last-
ing hours--days), the endothelial cells· beconm damaged or 
Si!I01len 1 and :nairo\v the lumen, of t;he microcirculatory 
system,. ~!he ad.herence of platelets, leucocytes and 
erythrocyter3 to the system's endothelium causes a further 
narrovling o.f the lumen.. r.rhis results in a stasis of blood 
ar.:.d increased edema formation.. r1any possible mediators 
have been implicated in these inii;ia.l "vascular" phases 
of inf'lammo.tion.. His-tam:Ln.e, serotonin, bradykinin, SRS 
(slow reacting substance), and the prostaglandins are a 
few examples of the chemical substances that are found. at 
the inflammatory site and are possibly responsible for the 
vasodilation and increased vascular permeabilityo 
Follovving the early vascular events, a greater 
number of granulocytes appear at the injured. area. It 
3 
is thought that these cells are attracted by chemical sub-
stances as yet undefined. This process is termed chemotaxis .. 
Many of the suggested inflammatory mediators as ~.,rell as the 
immunologically activatecl complement components are pur-
ported to have chemotactic properties., Tbe g:carmlocytes 
m~rg:lnate or actherc~ to the vessel lumen and migrate across 
the endothelium into the inflammed area.. 'JJho 11 cellular 11 
aspects of inflammation have no'ltT been initiated. They are 
characterized by a localization of the inflammed site and 
local tissue destruction.. The previously described vascu-
lar stasis is nO'IJ:T accompanied by the formation of loosely 
organized fibrin clots. This process walls off the inflammed 
area from the rest of the body and the local metabolism 
changes from aerobic to anaerobic with subsequent tissue 
necrosis. The diapedesis of granulocytes into the site of 
inflammation results in phagocytosis of the destroyed tissue. 
The phagocytes release lysozomal enzymes which cause further 
tissue destruction and edema formation. The process, a.s 
described.up to this point, has been generally termed the 
"exudative-degenerative stage 11 of inflammation. As this 
phase is terminated (by :processes that are not well 
understood), the final stage of inflammation characterized 
by fibrous tissue growth is started. These two stages may 
overlap -- tissue degeneration may predominate at the 
center of the inflarnmed area with fibrous tissue prolifera-
tion at the periphery. The stimulant action of the inflarnma-
tory process is necessary for normal tissue repair or healing 
(4). 
The primary stimulus that initiates new connective 
tissue synthesis at inflammatory loci is not l01o~n1. The 
repair process begins by a proliferation of fibroblasts and 
small blood vessels v,rhich penetrate the exudate. 'l'he resul-
tant highly vascularized reddish mass is termed granulation 
tissue. The granuloma eventually replaces the inflammatory 
e:x-v.do.te. •rhis phase of infhunmation is refex·red to as the 
"reparati\re or proliferative sta(J_;e".. The amount of fibrous 
tis~r1.1e g:ro"trt.h is usually dependent on the type of inflamma-
tion~ Acute and chronic inflammatory lesions follow similar 
patterns of tissue repair't but quantitatively more fibrous 
tissue is formed following a mild but prolonged inflamma·· 
tory process (l~): The proliferative stage of inflammation 
is also susceptible to loss of homeostatic control and 
exeess fibrous tissue formation :i.s a usual symptom of and 
complication in rheumatoid arthritis. 
This description of the inflammatory process is 
rather brief and some\<lhat simplistic, .but it points out 
. that there are many possible ltlays for therapeutic agent·s 
---------
to. exert anti-inflammatory actions. It is doubtful that 
all clinically useful anti-inflammatory agents have the 
same mechanism of action.. It is equally doubtful that a 
single compound would have an encompassing action for 
arresting or preventing all of the inflammatory processes. 
1l'he many mediators proposed to cause increased vascular 
permeability, the involvement of' the blood clotting and 
phagocytic systems, the immunological aspects, plus the 
diverse biochemical changes coupled with the autonomic 
responses of the body to all of these actions sugges·l; 
that ideal anti-inflammatory therapy could involve the 
use of many different and as yet unconventional agents. 
The central nervous system v.ras proposed as one of 
the regulatory sites of inflammation as early as 1845 (7).' 
5 
Since that time, it" has been demonstrated that t·he inflamma-
tory response can be attenuated or abolished b;y spinal 
transection (8) and spinal injury (9), sensory nerve.block-
ade (8)~ acute or chronic denervation near the inflammatory 
site (8), and by medical hypnosis (10). Inflarnma,cory 
lesionH can also be induced by experimental antidromic 
excitation ·through afferent sensory nerves (11,12),. This 
lat;ter sit;uation resembles the effect of exogenous noxious 
stimuli on a limited zone of tissue .. 
A l!vide variety of centrally-acting drugs have been 
sho,,vn to possess anti-inflammatory activity in a variety 
of experimental models. The anti-inflammatory effects of 
chlorpromazine, reserpine, .iproniazid ano. morphine (13), 
---------
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as well as the tricyclic antidepressants (14), have been 
. well documented in laboratory animals. The 'anti-inflammatory 
effects of morphine (15~16) were found to be reduced or 
abolished by adrenergic blocking drugs or by extirpation of 
sympathetic ganglia. This indicates that the efferent path-
ways concerned with inflammatory inhibition by morphine are 
sympathetic fibers. Inhibition of inflammation by the tri-
cyclic antidepressants has been shown to be abolished by 
adrenalectomy, adrenal demedullation, pretreatment with 
reserpine or guanethidine and by inhibitors of noradrenalin 
biosynthesis (14). Arrigoni-Martelli et alo (14) have con-
cluded that the anti-inflammatory effect of antidepressant 
drugs is due to the inhibition of catecholamine uptake thus 
potentiating the effects of these amines. The same conclu-
sion can be applied to iproniazid and to the majority of 
other drugs knownto be monoamine oxidase inhibitors since 
they would also serve to potentiate the effects of endogenous 
catecholamines. Reserpine is a known releaser and depletor 
of boi;h norepinephrine and serotonin in the central nervous 
system and in the periphery. Moreover, chlorpromazine is 
knovm to have significant effects upon monoamine metabolism 
(1'7). 
Spector and Willoughby (18) have suggested that 
local inactivation of anti-inflammatory amines (probably 
adrenalin) may contribute to the development of inflammation. 
In support of this hypothesis, Northover (19) pas described 
the effects of monoamine oxidase inhibitors on vascular 
,. 
permeability, ~1oller (20) has noted the disappearance of 
catecholamines from injured tissue, and Raek~lllio (21) 
7 
has demonstrated increased monoamine oxidase'activity in 
injured skin. Willoughby and Spector (22) have shwon DOPA 
(Dihydroxyphenylalanine), dopamine, norepinephrine and 
adrenalin to be anti-inflammatory in turpentine-induced 
pleurisy and they suggest that the destruction of these 
substances may be increased during the inflammatory process. 
The central nervous system serves another role in 
the regulation of an inflammatory response. As described 
by Selye (23), stress (inflammation being one example) is 
capable of activating the pituitary-adrenal axis to release 
endogenous corticosteroids. This activation is believed to 
be mediated via the hypothalamic-hypophyseal portal system 
by th(.; corticotrophin releasing factor (CP..F). 
The effects of some anti-inflamma.tory agents have· 
been partially ascribed to their capacity to effect a 
release of corticosteroids from the adrenal gland. As 
early as 191+9 1 Calesnick and Beutner (24) considered the 
possibility that the therapeutic effect of salicylates in 
inflammation might result from a stimulation of the adrenals. 
Keleman !2.'!z. g. (25) demonstrated in rats that high doses of 
salicylates were capable of decreasing total number of 
eosinophils, causing the histological signs of stress in 
thymus, spleen and adrenals and depleting ascorbic acid 
and lipids from the adrenals.. Most of these effects were 
prev·ented by adrenalectomy prior to the experiments. These 
8 
authors stressed the fact that these provocative findings 
could only be attributed to very high doses of salicylates. 
Many authors have debated whether or not this steroid-
releasing potential plays any significant part in the anti-
inflammatory clinical effectiveness of these drugs. 
Domenjoz (7) finally concluded that some of the anti-
inflammatory compounds do cause a release of endogenous 
steroids, but this phenomenon only partially accounted for 
their anti-inflammatory effectiveness. 
In 1964, Robichaud et al. (26) noted that cryogenine 
(an alkaloid isolated from Heimia salici.folia IJink and otto) 
possessed unique ataractic properties in both rats and dogs •. 
During gross observational screening, this tranquilizing 
capability was not associated with either ataxia or anal-
gesia. Pa:centerally, the drug produced hypothermia similar 
to the effects of reserpine and of ·!;he phenothiazine deriva-
tives, but it did not produce diarrhea, blepharoptosis and 
other reserpine-like symptomatology. nor did it produce 
phenothiazine-like relaxation of skeletal muscle tone. The 
tranquilizing potential of cryogenine v;as investigated 
further using both discrete and continuous avoidance test-
ing in rats (2'1).. Cryogeni.ne demonstrated anxiety-reducing 
properties with very few side effects when compared to 
chlorpromazine.- Because of a shortage of this rather rare 
alkaloid, the early experiments were severely limited as to · 
the number of experimental animals tested. A recent and 
more comprehensive . investigation by Nucifora and IVJalone (28) 
r 
confirmed cryogenine's neuroleptic properties (when given 
intraperitoneally) in a.iscrete avoidance behavioral test-
ing (pole climbing), but they found the drug to be much 
less active in continuous (Sidman) avoidance tests than 
the previous study had suggested. It should be noted here 
that the neuroleptic capacity of cryogenine has never been 
demonstrated upon oral administration of the drug and that 
the toxicity and lethality vary markedly with the route of 
administration utilized (in the rat: the intraperitoneal 
LD50 = ?8.0 mg/kg while the oral LD50 is greater than 1000 
mgJkg) (26). 
Cryogenine has also been shown capable of increas-
ing the pressor response to exogenous epinephrine in the 
Dial-Urethan anesthetized cat (26) and to decrease (low 
doses) and to increase (high doses) this response in the 
9 
same preparation (29). Experiments in urethan-anesthetized 
dogs demonstrated a similar biphasic effect (29,30). · Since 
cryogenine seemed to lack affinity for the adrenergic 
receptor of the rat va~ deferens (29) and to have no effect 
upon s;y-mpathetic ganglia (31), it is possible that such 
alterations in the response to exogenous epinephrine could 
be due to changes in the metabolism, uptake or release of 
catecholamines within the sympathetic nervous system or to 
some :involvement wi'Gh the parasympathetic system. 
In 1966, a report by Jiu (32) indicated that alcoholic 
extracts of Heimia salicifolia possE;Jssed anti-inflammatory 
properties in both ·yeast-induced paw edema and cotton pelle·l; 
L 
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granuloma studies. This intensified ongoing research in 
our laboratory and in 1967, Kaplan et al. (33) reported 
that cryogenine (given orally) was approximately equipotent 
to phenylbutazone at inhibiting carrageenin-induced pedal 
edema and Mycobacterium adjuvant-induced polyarthritis. 
This work was later confirmed in more extensive studies 
by Chang et al. (34), Kocialski et al. (35), and by 
Kosersky et al. (36). 
Gryogenine has also been shown to possess anti-
inflammatory properties in 45°0 thermal edema (37), guinea 
pig ultraviolet erythema (36), and serotonin-induced pedal 
edema (33). It is also capable of suppressing bradykinin-
(37) and histamine-induced capillary permeability (33), 
and of reversing the hematological changes caused by 
A structural resemblance of tetrabenazine, a benzo-
quinolizine derivative (Fig. la.), to possible metabolic 
breakdown products of cryogenine (Fig. lb.) has led to the 
use of tetrabenazine as one of the reference standards in 
the pharmacological evaluation of cryogenine (28,34,3.5,37., 
39)... In 1971, Chang et. al. (31+) demonstrated for the first 
time that tetrabenazine possessed signif'icant anti-
inflammatory properties as evidenced by inhibition of 
carragcenin-·induced pedal edema. This effect has been 
confirmed by Kocialski -~~- al. (35) •. Nore receniily, tetra-
benazine has .also been shov-m to be capable of suppressing 
'4 ° 1 . . 5 C therma . edema J..n rats (37) •. Tet;rabenazine~ in a 
Fige 1 -- Structures of: 
a. Cryogenine 
b.. Benzoquinolizine dBrivates 
--------
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a. 
b. 
similar manner to reserpine, lowers the brain levels of 
serotonin and norepinephrine; however, unlike reserpine 
tetrabenazine has little or no effect upon the peripheral 
levels of these amines (40,41). 
13 
Regarding the benzoquinolizine derivaties synthe-
sized to date, there seem to be two distinct pharmacologic 
classes. Compounds such as tetrabenazine (40,41) and RO 
4-·128L~ (L~2,43) (Fig. lb.) deplete the brain. of serotonin 
and norepinephrine and produce a typical reserpine-like 
syndrome consisting of miosis, hypothermia, hunched back, 
salivation, lacrimation and extrapyramidal symptoms. other 
derivatives such as benzquinamide (~~,45) and RO 1-9564 
(46,47) are ataractic without an associated depletion of 
brain amines or a reserpine-like syndrome. These latter 
agents are ·thought to act by a more direct mechanism than 
an involvement 'trith brain amines (41) .. 
Although cryogenine and tetrabenazine share ataractic 
and anti-inflammatory capabilities~ as well as some struc-
tural similarities, there seems to be a number of differences 
in regard to the general pharmacology of the two drugs. .As 
stated. previously, cryognine displays therapeutic effects 
·without a t;ypical reserpine-lil(e syndrome -- in ·this respect, 
cryogenine resembles the benzquinamide and RO l-·956l.f. class 
o.f benzoquinolizines. It \'ms of interest to us to inves·ti-
gate any similarities between cryogenine and the two classes 
of benzoquinolizines as to a.mine-clepleting potential, 
ataractic properties and anti-inflarrnn~tory ·capabilities. 
These two classes of benzoquinolizines also differ 
in another· respect. Tetrabenazine (48) and RO 4-1284-
(49,50,51) e.ffect a release of endogenous corticosteroids 
as does reserpine (52,53,54), but benzquinamide and 
14-
RO l-956L} ( L~9) seemingly are without effect upon endogenous 
steroid release. 
Previous studies (36,37) have indicated that 
cryogenine does not appear to release corticosteroids 
from the adrenals at anti-inflammatOJ.'Y dosage levels, but 
this has never been sho~rn by direct measurement of steroid 
levels or by retention of anti-inflammatory capabilities 
after adrenalectomy. Therefore, an attempt has been made 
in this study to document the anti-inflammatory properties 
of cryogenirie and of both classes of benzoquinolizines and 
to see if there is any correlation of such properties v:ith 
the release of endogenous steroids. It seemed_ desirable to 
carry out this investigation using two dissimilar types of 
induced inflammation. ~'he cotton pellet granuloma test \'Jas 
utilized as a model of proliferative inflairs.rnation, while 
the carrageenin-induced pedal edema assay was utilized as 
a paradigm of exudative inflammation (13). It was felt that 
by testing th(~ previously mentioned drugs using these two 
different; models of inflammation in both intact and adre .... 
nalectomized animals a distinct· and pharmacologically sig-
nificant profile coulcl be developed for each compound. 
MATERIALS AND METHODS 
Tissue serotonin and norepinephrine levels 
Male Wistar rats (200-400 g) were obtained from · 
Albino Farms Inc., Red Bank, N. J. and kept in this labora-
tory for at least one week prior to testing. Water and 
u food (Pl..trine. Laboratory Chow) 'l.'lere allo\'lred gd l:iJ2.i tt!!!!, up to 
the time of injection. The animal quarters were kept at a 
constant temperature of 72-75°C and the lighting was extin-
guished at approximately the same time everyday to simulate 
diurnal patterns. All drugs were dissolved in glacial 
acetic acid and cliluted with distilled water to an acid 
conct-:mtration of 2"0%.. ~~est agents t>rere administered intra-
peritoneally at a constant dosage volume of 5 mlA{g and 
2.0% acetic acid (5 ml/kg) was used as a vehicle control. 
~~he animals \'Jere sacrificed by decapitation either 2 or 4 h 
after inject;ion.. Time of sacrifice was kept bet-v:een 9-11 a.m. 
to minimize diurnal variation in amines. The brains and 
hearts \vere rapidly excised, placed in polyethylene bags, 
and immecl.iai;ely .frozen in a Cl~t'Y ice-acetone bath. All 
tissues were then stored in dry ice until the time of assay. 
Serotonin and norepinephrine were assayed according to the 
. . 
~1ead-I!'inger modification (55) of the techniques of Shore 
a.nd Olin (56) as adapted by B. K. Koe (5?). 
Brains were quickly weighed, while frozen, to the 
nearest 10 mg and homogenized in t\..ro volumes of O.OlN HCl 
' 15 
in an all-glass homogenizer (Kontes Glass Co., 15 ml 
Tenbroeck) driven by an electric drill and cooled in an 
icewater bath. A volume o~ 2.5 ml o~ the homogenate was 
added to 120 ml screw-capped bottles containing 4 g NaCl 
and 30 ml of NaCl saturated n-butanol equilibrated with 
- . 
O.OlN HCl (see Appendix A-I-A). The bottles were placed 
in a vertical shaker ~or 0.5 h and then centrifuged at 
16 
2500 RPI1 using an ICE ~loor-model centifuge for 3 to 5 min. 
After this, 20 ml of the butanol layer were pipetted into 
clean bottles containing 35 ml ~-heptane (Fisher Sci. Co.) 
and 2.5 ml of O.OlN HCl and shaken for 3 min. After c·entri-
fugation for 3-5 min, 1.0 and 1.5 ml of the acid layer were 
removed for the serotonin and norepinephrine assays, respec-
tively. Standard amounts of serotonin creatinine sulfate 
monohydrate (Calbiochem) and l·Marternol bitartrate mono-
hydrate (Winthrop Labs Inc.) were prepared daily (see 
Appendix A-I-N) and added to 2.5 ml pooled homogenates and 
reagent blank, then carried through the entire extraction 
procedure to determine percent recovery. These compounds 
also served as standards (see Appendix A-V). 
Hearts were prepared in a similar manner except 
that the tissue .,.,as weighed and placed in polyethylene bags 
and frozen in liquid nitrogen., It 1rras then placed in a 
tablet ·punch similar to that described by Callingham and 
Gass '(58) and pulverized to .facilitate homogenization and 
extraction~ A volume of 5 ml o~ O.OlN HCl per g of heart 
tissue 1rms used for the homogenization pro.cedure. \vith 
-
F. 
1? 
tetrabenazine-treated animals, the tissues had to be 
pre-extracted with three 20-ml volumes of reagent grade 
chloroform, each being shaken for 5 min, centrifuged and 
the chloroform layer removed by aspiration (see Appendix A-
VI-C). 
In determining serotonin, 0.3 ml of concentrated HCl 
was added to a 1.0 ml portion of the extracted homogenate. 
The mixture was placed in a 1 em quartz cuvette and read 
immediately in an Aminco-Bowman spectrophotofluorometer 
with activation and emission wave lengths set at 295 and 
540 millimicrons, respectively. A lp-21 phototube and slit 
system #4 were used. 
The 1. 5 ml norepinephrine aliquots 1t1ere mixed with 
0 .. 5 ml of acetate buffer (see Appendix A-I-I). To this was 
,,,;. added 0 .. 05 ml of O.lN ioclino in o.bnolutc ethanol (sec 
Appendix A-I-K) and the tubes allmved ·!;o stand for ,6 min 
afte~~ which 0.1 ml of 0.05N sodium thiosulfate (see Appendix 
A-I-J) was added. This was followed by the immediate addi-
tion of 0.5 ml alkaline ascorbate solution (see Appendix 
A-I-M) prepared just before use.~ 'l'he tubes were then 
irradiated for 20 min under two 20 1 ratt fluorescent lamps. 
One ml of the resultant solution was placed in 1 em quartz 
cuvettes and read in the Aminco-Bo\'nnan spectrophotofluoro-
meter with an activation wave length of 410 millimicrons 
and an emission \vave length of 510 millimicrons.. Spectral 
curYes for both serotonin and norepinephrine \"l~re taken for 
the tissues samples, spiked tissue samples, and standard 
18 
during each set of determinations. 
Fluorescence units per meg of spiked amines were 
determined by averaging the readings of three concentrations 
of exogenously added amine and 1trere used to calculate the 
amine levels of the samples in meg per g of wet tissue 
(see Appendix A-V).· Mean amine levels (7 animals per group) 
were determined along with respective standard errors. Sig-
nificance between means was calculated by analysis of vari-
ance methods (59). 
Drugs tested included: reserpine acetatea 10 mg/kg, 
tetrabenazine acetateb 50 mg/kg, cryogenine acetatec 50 mg/kg, 
and 70.'7 mg/kg -- each assayed four h after injection. 
Cryogenine acetate (70.7 mg/kg) was also tested two h after 
injection. Vehicle controls of 0.9% saline and. 2.0% acetic 
acid \vere also eV"aluated at '-!- h afte::t." injection. 
Cotton ;e.~].let granuJ.o_ma inhibition .~saz 
Iviale Sprague-·Dal<Tley rats (98-216 g) were obtained 
from Horton's Laboratories Inc~, Oakland, Calif. Food 
(Purina I..a.boratory Chow) and tap water were allo-vred ad libitum 
-~ 
up to and through ·the assay procedure unless other\'lise speci- ~ 
fied., !J!he environmental temperature vms maintained at 
72-75°C and ·[;he quarters were illuminated from approximately 
a - :Purchased from Nutritional Biochemicals Inc~ 
b - Obtained from Hoffmann-LaRoche Inc. 
c - Obtained from Dr. A. E. Schvmrting, University of 
Connecticut, School of Pharmacy, Storrs, Conn. 
7 a.m .. to 5 p.m. ·daily. vlhen adrenalectomized animals 
were utilized, the tap water was replaced with 1% NaCl 
with all other conditions remaining the same. 
The method utilized was similar to that of Meier 
et al. (60). Pellets (10.0 mg ± 0.5 mg) were hand-rolled 
from non-sterile, raw, chopped cotton to a uniform size 
and the weights rechecked after the rolling procedure. 
The animals were placed under light ether anesthesia and 
their backs shaved with an electric clipper. A single 
transverse skin incision was made in the dorso-cau"dal 
region and t\tJ'O pellets \':ere placed in the dorso-lateral 
superficial fascia approximately 2 em caudal to the 
should~)rs. The skin was closed t'lith metal \'round clips. 
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In experiments utilizing adrenalectomized. animals, 
the r·ats Wf.!:t'e bilatel."ally adrenalectomized and the pellets 
irnmE~diately implanted in the· same region through the t\•TO 
1ong:ttudi.nal incisions required f01" the surgery. As 
soon as the animals t'lere ambulatory (in e.pproximately 
15 min), i;hey were dosed orally (18 gauge feeding needles) 
vdth the test medications and injected. subcutaneously 
with 0.1 ml of a combination of 1% potassium penicillin G 
(E .. R. Squ:i.bb #6'736) plus 196 streptomycin sulfate (Jni 
Lilly i~587) solution caudal to the skin incision. 
The animals \tlere then g:iven the test· drugs orally 
at approxim.!J.tel;y the same time everyday for the nex-t five 
-
20 
days. a All test drugs were dissolved or suspended by 
trituration in 0.25% agar and administered at a constant 
dosage volume of 10 ml/kg. On day +3 they also received 
another 0.1 ml of the antibiotic combination. Approxi-
mately 24 h after the last test drug injection, they were 
sacrificed by decapitation. The cotton was then excised 
and both pellets placed on a preweighed section of aluminum 
foil. The foil (plus pellets} was immediately weighed. 
~~he pellets were then dried (80°C for 18 hr) and reweighed. 
Wet and dry pellet weights were calculated by subtracting 
the .foil and cotton weights from the total \'let and dry 
weights. These weights \'!ere also expressed as mg/100 g 
of final body weight. Wet th;y·mus and adrenal weights \v-ere 
expressed in the same manner. Mean values for all these 
metamet;ers wert: calculatecl along with t;hei.~" respective 
s·tandard errors. Significance between means \'tas calculated 
using Student 's t t es·!i • 
- -
....... -, .. ~-----
a - The follo~tling drugs were used: hydrocortisone base 
(Sigma Chem:Lcal Co. i~lH4001), indomethacin (Merck Sharp 
&~ Dohme #L-590226n·00AlOL~), phenylbutazone (Geigy 
Pharmaceuticals f,.iSN462L~1)., reserpine (Nutritional 
Biochemical Corp$ #1000) 9 chlorpromazine HCl (Smith 
Kline &. French f)2601-A) ~ tetrabenazine (Hoffmann-
I.~aRoche f..tC/421) ~ bexu~quinamicle (Chas. Pfizer 8G Co .. , 
Inc .. fJp-26L~7)., R04-12c}q. (2-hydroxy, 2-ethyl, 3-isobutyl, 
9-10--dimethoxy, 1,2,3,lJ·,6,7-hexahydro-llb H'- . · · 
benzoqu:i.nolizine) (Hoffmann-LaRoche)~· ROl-956'+ (2-hydroxy, 
2-i.sobutyl, 3-eth;y·l, 9-·10-dimethoxy, 1,2,3,L~.,6,7~-hexahydro­
llb H*·benzoquinol:i.zine) (Hoi'fmann~<LaRoche), and sodium 
pen.obarbi tal (1'1allinckrodt #6593).. Cryogenine base {,lfas 
isolated courtesy of Dr .. John K .. BrO\•m and Stanley T. 
Omaye using~the method of El-Olmey (61). Purity of 
c:r:yogenine was established by IH, thin-layer chromatography 
and .. mixed melting point determinations. 
I -
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garrageenin-induced pedal edema 
Male Sprague-Dawley rats (200-2?0 g) were obtained 
from Horton's Laboratories Inc., Oakland, Calif., and main-
tained as in the cotton pellet granuloma assays. 
The methods used v-1ere similar to those described 
by Van Arman et ~· (62). The animals ,.,ere taken off food 
at -1 h, weighed, marked and dosed orally with the test 
drugs using 18 gauge feeding needles. The test drugs were 
dissolved or suspended in 0.25% agar and administered at a 
constant dosage volume of 10 ml/kg. Control animals received 
only the agar vehicle.. At 0 h, subplantar pedal injections 
of 0 .. 1 ml of an aged, 1% aqueous carrageenina solution were 
made using a 5/8 inch, 25 gauge needle and a 0 .. 25 ml. 
precision-grade glass syringe. The leg was marked at the 
ankle joini; using a permanent-type fel·t-tipped ma:r•ker and 
all control paw volumes were record~d plethysmographically 
to this mark .. 
The apparatus used i'or recording paw volume con-
sistec.l o:r a milled Perspex well (approximately 25 ml in 
volume) filled with mercury and connected by.n.n S-shaped 
glass ·tubing (5 mm I.D .. ) to a Statham P-23 BB transducerb 
filled ,,.,ith distilJ.eo. V!Hter.. v-olume changes in the meroury 
reservoir due to an immersed object can be measured as 
---........ ~~·-·""---
a - SeaKem Type I, Sea:plant Chemical Corp .. , New Bedford, 
fvlnss .. (lot #312803).. Solution was aged for at least 
two weeks prio:r to use~ 
b- Manufactured by Statham Laboratories, Inc., Hato Rey, 
Puerto Rico .. 
----- ---
----- -------------------
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pressure changes.. The transducer signal was then amplified 
and recordeda by a heated stylus. A resistor-capacitor 
networkb was necessary to filter outbackground noise 
present at the levels of amplifier sensitivity needed. 
Calibration of volume changes was accomplished by 
introducing a uniform-diameter Perspex rod attached to a 
stereotaxic unit (Narishige #2321) into the mercury reser-
voir. The micrometer scale had been previously calibrated 
in ml of water displaced per mm of vernier displacement. 
The animals \'/ere held loosely and the injected leg 
was fully extended by exerting pressure just above the knee. 
The hind paw was then immersed in the mercury up to the 
reference mark on the ankle. A total of three immersions 
was used to·determine the average paw volume of each.rat 
a·t; each time period., 
Degree of ea.ema T/las calculated by subtracting the 
c01rcrol paw volume ('taken immediately after carrageenin 
in,jection) from the inflammed pa'l."l volume and computing the 
mean and standard error for each group. Statistical sig-
nificance between groups was determined by Student's t test. 
The follot"li:ng drugs were studied: tetrabenazine, cryogenine, 
benzquinamide, HO '+--12'+8, and RO 1-9564- (same lot numbers 
as noted earlier). 
---=----·---
a - A Beckman D;:rnograph (type RS) -':las used as manufactured 
by Beckmaninstruments, Inc., Schiller Park, Ill .. 
b - Modifieation of the Dynograph was provided by r1r .. li'ra.nk 
A.,. McKenna of· .Beckman Instruments_, Inc. 
--- -
-------- ------------------
RESULTS 
Tissue serotonin and norepinephrine levels 
When one quantitates amines from biological tissues, 
the extracted amines must have the same activation and emis-
sion expectra as chemically pure reference standards. In 
Figs. 2-3, it can be seen that the fluorescent spectra of 
serotonin and norepinephrine added to and extracted from 
pooled brain homogenates are almost identical to those of 
their respective standards. The emission spectrum for 
norepinephrine peaked at 510 millimicrons, which value 
agrees with _previously reported values (56). There \'las 
only a ·10 millimicron difference bet;t,veen the experimentally·-
obtained serotonin peak (51.1·0 millimicrons) and that previously 
reported by others (550 millimicrons) (57). \'/hile there \1/ere 
slight spectral shifts observed from day to day, this 'IJlas 
compensated for by obtaining daily spectral curves and 
adjusting both the activation a.nd emission monochromators 
to the peale values for each day. Similar spectra were 
obtained for endogenous norepinephrine ano. serotonin 
extracted from brains and hearts. Activation spectra for 
both amines in both tissues were similar. Figs. 2-3 also 
show the very low background fluorescence obtained from 
the reagent blanks carried th.rough the en·l;ire extraction 
procedure.··· 
To determine percentage recover;y a.ncl to serve as a 
23 
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l!,ig. 2 -- Fluorescent spectra of: 
o· Serotonin standard (l.o5 meg). 
0 Extracted serotonin (1.5 meg) 
added to pooled brain homogenate. 
0 Reagent blank. 
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Fig. 3 -- Fluorescent spectra of: 
0 Norepinephrine standard (1.0 meg). 
G E-xtracted norepinephrine (1 .. 0 meg) 
added to pooled brain homogenate. 
C Reagent blank. 
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standard curve, krio~m amounts of exogenous serotonin and · 
norepinephrine were added to pooled tissue homogenates and 
carried through the extraction procedure. Fig. 3 illustrates 
the linearity of fluorescence of exogenously-added amines 
over the ranges normally encountered for endogenous amine 
levels. A fluorescence ratio of extracted spiked samples 
to the amine standards (as described in Appendix I-V-E) was 
used to determine the percent recovery for each assay. The 
mean recovery for the serotonin assays was 69.2% (.±. 2.0 S.E.) 
and for norepinephrine 64.5% (.±. 2.2 S.E.). 
As summarized in Table I, reserpine acetate (10 mg/ 
kg) lowered brain sero"t;onin and norepinephrine levels by 
81.5% and 91.. 5% respectively. Heart amine levels were 
lowered 39~7% for serotonin and 91.5% for norepinephrine. 
All of 'thE:se ;d.epletions we~ce st;at;:i.stically significa.nt 
(P ( 0,.001). Te·trabenazine acetate (50 mg/kg) significantly 
(P (0.001) depleted brain serotonin and norepinephrine by 
69.8% and 82.1%, respectively. As expected,_heart levels 
were lO\V"ered by a non-significant .. 6 .. 2% and 9.8~6 relative 
to the acetic acid control group. 
The results in Table II indicate that cryogenine 
acetate at 50 mg/kg caused a slight (9,.6%) but statistically 
significant (~ ( 0 .. 01) lowering of whole brain serotonin 
levels. T_his ctepletion, however, \'las not corroborated at; 
70~7 mg/kg nor were there any other significant changes 
in either dosage group.. The peak ataractic effect of 
cryogenine occurred approximately 2 h after I.P. injection. 
Fig .. 4 -- s-t·andard curves of e,xogenous amine added 
to and extracted from a pooled brain 
homogenate. 
Values indicate total percent ·transmission 
minus the pooled brain homogenate: 
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Table I -- Effect of intraperitoneally administered 
reserpine acetate and tet-rabenazine acetate 
upon tissue·amine (5HT =serotonin.; NE = 
norepineph!."ine) 1eYels expressed as mcg/g 
wet \'Ieight., 
Dosages of reserpine and tetrabenazine are 
expressed as rng of base/kg. 
Control 
Tissue 2 % HOAC (S.D.) 
5HT 0.535 (0. 023) 
Brain 
NE 0.446 (0.036) 
5HT 0. 527 (0.090) 
. Heart 
NE 0.933 (0 .154) 
Control 
2% HOAC 
5HT 0.486 (0. 093) 
Brain 
NE 0.430 (0.036) 
5HT 0.614 (0. 057) 
Heai .. t 
NE 1.015 (0 .14:3) 
',JIIIIJ'lf,~,,,,,,,,I',',',H'If,!'\f' 
Reserpine HOAC 
10 mg/kg (S.D.) 
0.099" (O. 01H) 
0.038 (0. 004) 
0.318 (0. 038) 
0.075 (0. 02~:) 
Tetrabenazin·e HOAC 
50 mg/kg 
0.147 (0. 027) 
0.077 (O.Ol~i) 
0.576 (0. 040) 
0. 915. (0 .181.) 
· ~w,;JJiWf'fr·· ~~:n.: .. 11i~ · .I.. I 
p 
< 0. 001 
< 0.001 
< 0.001 
< 0.001 
< 0. 001 
< 0. 001 
> 0.200 
> 0.250 
\.W [\) 
.I ·I ill' I ·'·!·"· L .II;.:IIW·II"!LLI :Jili!l .. L.ill. ... ll. 1:.. JIL!L 
I'' 
1
11 1,1 
--------·------ --- -
- -----·-------- - ----------------
Table II -- Effect of intraperi-lioneally administered 
cryogenine acetate upon tissue amine levels 
expressed as mcg/g v1et weight .. 
Dosage of cryogen:i.ne is expressed as mg 
of base/kg. 
i_ 
~= 
Tissue 
5HT 
Brain 
NE 
5HT 
,Heart 
NE 
5HT 
Brain 
NE 
5HT 
Heart 
NE 
"""' ;.i.;L__-----~~=~-~~~--------:11 
Control 
2% HOAC 
0.621 
0.534 
0.737 
0.598 
Control 
2% HOAC 
0.735 
0.455 
o. 823 
1.047 
I J1111Wll1!~:=: 1,IV 1• 1 Il 11.~·~"~~, 
Cryogenine HOAC 
(S.D.) 50 mg/kg · (S.D.) p 
(0. 029) 0.561 (0.048)" < 0.010 
(0.030) 0.504 (0.074~) > 0. 500 
(0 .127) 0.638 (0. 084:) > 0. 500 
(0. 052) 0.638 (0. 084:) > 0. 500 
-
Cryogenine HOAC 
70.7 mg/kg 
(0.069) 0.735 (0. 063) > o. 500 
(0. 070) '0.470 (0. 043) > 0. 500 
(0 ,146) 0. 829 (0. 138) ) 0. 500 
(0. 084) 1.103 (0. 061) > 0.100 
. [, L :;1 :; 11\-·+·-. -JI_F:Ji~-l,lr~~lr.:.: .-. 11r.·, L.l ... 1 :llf!i! ,t: \"!' .'. CJII:,q~ll IlL IJ:.LJJ,Il!II,J,I :JIL II. ,.I 
\),I 
.;::-
~~~-------- -----
----~-- ~- -
-- - -
- ----------------
--~---
Cryogenine acetate (70.7 mg/kg) 2 h after injection 
produced no amine depletion (Table III) but did cause 
a significant (P ( 0.05) rise in heart norepinephrine 
levels. Attempts to utilize higher doses of cryogenine 
(100 mg/kg) were unsuccessful due to death of the animals 
before the four-hour experimental period had elapsed. 
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To determine if the 2% acetic. acid vehicle affected· 
amine levels, 0.9% saline was assayed against 2% acetic 
acid. The results in Table IV show that there was a sig-
nificant lowering of brain serotonin levels with no effect 
upon brain norepinephrine or cardiac amine levels. 
Cotton pel_l.eJc granu]-opa inhibition assays 
Preliminary experiments had indicated tha·c many of 
tl).e comp~Y:J.:cJ.c\s used in this study would affect body weight 
gain.. The::t•efore, it \<Tas of interest to deter•mine the 
effects of short term food deprivation and dehydration 
upon the various metameters. Table V outlines the effects 
of food d.eprivation, dehydration, and food deprivation 
+dehydration for the 1~.8 h period just preceding sacrifice 
of the animals.. It can be seen that in all the test groups 
the body 1.r1eight gain was negative as compared to the con-
trol group which gained 38.2 g.. This body vveight loss \'las 
accompa~ied by a decrease in thymus ~>~eight \~Jhich '"as sig-
nificant for the "starvation" group (P ( 0 .. 001). There vms 
also concomitant adrenal hypertrophy and a decrease in the 
weight; of the \~Jet granulomas --- all of which Ner·e significant 
-
f 
Table III -- Effect of intraperitoneally administered 
cryogenine acetate. upon tissue amine levels 
expressed as mcg/g wet weight. 
Cryogenine dosage is expressed as mg of 
base/kg .. 
Tissue· 
5HT 
Brain 
NE 
5HT-
Heart 
NE 
Control 
2% HOAC' 
o. 729 
0.444 
0.954 
0.826 
(S.D.) 
(0. 046) 
(0. 031) 
(0 .141) 
(0.070) 
-- Cryogenine HOAC~ 
70.7 mg/kg (S.D.) p 
o. 723 
0.426 
0. 926 
0.957 
(0.03H) ) 0.500 
(0. 04~!) > 0. 2 50 
(0.12~3) > 0.500 
(0 .• 08:3) < 0. 005 
a. Animals sacrificed at + 2 hrs. after dosing.' 
I i 1film91IT!~~-~ i 11!1 1 l~;l!~l·iP ' .I 11f ~-i .-IH····:i[l-Hf·"l:.JL ... "[II: I I I .. I 
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Table IV -- Effect of intraperitoneal control 
:injections of acetic acid upon tissue 
amine levels expressed as mcg/g wet 
weight .. 
~-
Tissue 
5HT 
Brain 
NE 
5HT 
Heart 
NE 
0.9% saline (S.D.) 
o. 770 (0.199) 
0.796 
0.658 
0.434 
1111111~111~"111111'1flll'l~ 
(0. 078) 
(0.075) 
(0. 020) 
( ~~,:nili"J"·H F1i"· 1111 : 
2% HOAC 
0.537 
0.739 
0. 610 
0.425 
. I 
(8. D.) 
(0.075) 
(0 .100) 
(0. 036) 
(0. 026) 
1..' 
p 
< 0.010 
> o. 500 
> 0.200 
> 0.250 
\.)J 
\0 
·''i'''n "+'"·: :n:.llfi'l!':. 1 1ri~::I::IFI'.:r:!t· 1, .. :. : .. H.IL:-
Table v -- Effect of food deprivation and dehydration 
upon cotton pc11et granuloma formation., 
~= 
'"IRI·III'"' -·--===--=-------------------------
Treatment !rlitial 
wt., g 
Control 125.5 
(2. 51) a 
Food Depri- 124.1 
vation c (5.30) 
Dehydration 
Food Depri-
vation + 
Dehydration 
129.0 
(6. 34) 
130.2 
(3.46) 
Body Thymus Ad::-enal. 
wt. gain, mg/lOOg mg/lOOg Wet mg g 
Non-adrenalectomized 
38.2 343.9 
(2. 51) (18.02) 
8 8***b 2 2 * 
- . - 7 .7 
(0. 86) (19 .14) 
-1.o*** 
(1.07) 
*** -9.5 
(1.44) 
298.4 
(21. 80) 
247.3*** 
(13.61) 
16.2 
(0.91) 
27 .2*** 
(1.45) 
23.2*** 
(0.56) 
27.1*** 
(1.23) 
338.4 
(20. 75) 
243.4*** 
(8.63) 
235.6*** 
(11.18) 
247.9** 
(11. 69) 
Granuloma wt. 
Dry mg %I Dry $I 
49.2 
(3.67) 
*>I<* 30.6 37.8 
(2. 71) 
ss.s~ 21.8· 
(2. 40) 
~* 34.4 30.1 
(2. 07) 
mg/lOOg 
30.2 
(2.45) 
26.4 
(1. 79) 
27.7 
(1.35) 
29.0 
(1. 99) 
12.6 
8.3 
4.0 
~· Figures within parentheses indicate the standard errors Qf the means (10 animals per group), 
b. *, **, and *~* indicate P ( .05, P ( ,01 and P (.COl, respectively. For ;all other values, 
p ).05. 
c. Food deprivation and dehydration were instituted 48 h before sacrifice. 
..p:-
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at P ( 0.001. Dry granuloma weight (expressed in mg) was 
inhibited by 37o9, 27.8, and 30.1%, respectively and these 
changes were all significant. Conversion of the granuloma 
weights to mg of dry granuloma per 100 g of final body 
weight reduced the inhibitions to 12.6, 8.3, and 4.0% with 
none of these changes being statistically significant. 
This indicated that the mg/100 g conversion should eliminate 
false-positive readings regarding granuloma formation due 
only to a drug's effect upon body weight. 
The effects of representative anti-inflammatory 
standards are summarized in Tables VI-VIII. Hydrocortisone 
(2.5 and 7.5 mg~cg/day) decreased body weight gain and 
thymus 111eight up to 30% with no statistically significant· 
effec·t; vpon adrenal weights... Both wet and clry g.re.nuloma 
1/Teights (mg) were significantly decreased and the inhibition 
of dry granuloma formation (up to 465''15) remained statistically 
significant after the mg/100 g conversion .. 
Indomethacin (Os2-lo8 mg/kg/day) seemed to facili-
tate body \-.reight gain relative to control animals and to 
slightly decrease thymus and adrenal ttreights.. There \'las 
some decreaHe in \-Tet granuloma ~reight; and a dose-correlated 
inhibition of dry granuloma formation by LJ ... 6, 12 .. 1, and 
22.7%. Approximately the same percent inhibitions were 
retained after the mg/100 g conversion. _ In b_ilaterally 
adrenalectomized rats, indomethacin had no consistent effects 
upon body or thymus \>!eights. It can be seen that in adre-
nalectomized control animeJ.s the thymus and granuloma weights 
--
~--
~-~-------
Table VI Effect. of orally administered 
hydrocortisone upon cotton pellet 
granuloma formation. 
lllffffiff!l'l•l!,lllllll•il'llllfl!l at:W:b ~-~===~-------------------------
' i 
Tre~.tment Initial Body Thymus Adreual Granuloma wt. I I 
(:ng/kg/day) wt.' g wt gain, mg/lOOg mg/lOOg wet mg n.ry mg %! Dry %I g 
mg/lOOg 
N Non-adrenalectomized 
--
(0) 10 153.4 25.3 235.0 13.5 145.8 23.8 
---
13.4 
(5.03}~ (2. 90) (17.6) (1. 6) (4.12) (1.77) (0.96) 
(2. 5) 10 154.0 25.9 230.6 15.8 ·*b 125.4"'- ** 16.8 29.4 9.2** 31.3 
(4.22) (1. 61) (16.4) (0. 6) (4.05) (1.03) (0.56) 
(7.5) 10 144.1 17.1* 165.5** 1.7.4 107.5*"' *8* 12. 46.2 7 .2*** 46.3 
(6.59) (1. 81) (10. 7} (1. 5) (2. 63) (1.12) (0. 34) 
a. Figures within parentheses indicate the standard errors of the means. 
· 15'. *, **, and *** indicate P (.05, P (.01 and P <.,.001,respectively. For all other values, 
- !:_).05. . - - -
~ 
.p. 
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'J:Iab1e VII Effect of orally· ad.minis'tered indomethacin 
upon cotton pellet graimloma .formationM 
Treatment Initial 
(mg/kg/day) wt., g 
,j,, ""'' 
Body Thymus 
wt. gain, mg/lOOg 
g 
Adrenal 
mg/lCOg Wet mg 
N Non-~dren~lectomized 
(0) 9 
' (0.2) 9 
(0.6) 10 
(1.8) 10 
(O) 11 
(0.2) 11 
(0.6-} 12 
(1. 8) 10 
120.5 33. •l 325.0 
(14.52) (2 .16)::. (2. 09) 
122.0 
(1.10) 
115.7 
(1.23) 
117.6 
(2 .16) 
39.1*£. 280.7 
(1.86) (18.44). 
36.4 
(1. 72) 
265.4* 
{20. 58) 
41. s** 3oo. 4 
(1.15) {26.88) 
18. :) 
.(0.69) 
""* 15.2 (0.68) 
19.2 
(O. 63) 
16.:~* 
(0. 8!~) 
273.3 
(13.34) 
278.1 
(24.03) 
236.3* 
(9. 34) 
238.3 
(14. 77) 
Aerenalectomized 
125.·9 
(1. 37) 
13.7 
(3.94) 
126.3 14.7 
(1.75) (3.61) 
132.7** 18.3 
(1.16). (4.02) 
132 . 1 ** 18. s 
(1. 4.2) (1;93) 
364.2 
(14.24) 
355.7 
(23. 55) 
420.3* 
(20. 06) 
371.6 
(13. 43) 
399.5 
(30 .42). 
420.2 
(39. 55) 
371.2 
(24.84) 
334.5 
(27. 00) 
Granulom!r;. wt. 
Dry mg I %I Dry 
mg/lOOg 
38.8 
(2. 69) 
40.6 -:-4.6 
(3.65) 
34.1 112.1 
(1. 66) 
25.6 
(2. 13) 
25.2 
(2.22) 
22.4 
(1.02) 
%I 
1.6 
12.5 
so.o*1 22.1 
(2. 46) 
. * 19.1 25.3 
60.6 
(4.10) 
59.4 I 2.0 
(5.24) 
ss.3 I 3.s 
(4. 59) 
(1.61) 
43.8 
(3. 36) 
42.3 
(3.76) 
38.7 
(3.07) 
3.4 
11.6 
47.6 21.4 31.3 28.5 *I ** (3. 64) (2. 17) 
a.. Figu~:es wi thi:n parentheses indicate the standl:'.rd errors of ·the mi~ans. 
o *, **, and*** indicate P <.05, P (.Cl and P (.001,respactively.IFpr all other 
values 2 ). 05. - -
) 
~ (J) 
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Table VIII -~- 1!:f'fect of orally administered 
phenylbutazone upon cotton peLlet 
granuloma formation. 
,. 
Treatment Initial Body Thymus Adrenal Granuloma. lwt. 
(mg/kg/day) wt., g . wt. gain, mg/lOOg mg/lOOg Wet mg Dry mg 1%! Dry %1 g mg/lOOg. 
N Non -adren<>.leo tomized L (0) 10 114.3 50.8 264.9 17.4 475.4 69.3 41.9 
(2.75)a (1.80) (14.24} (1.23)' (35.78) (4.71) I (2 .83) 
(10} 10 109.3 41.4**b 273.9 17.5 424.2 56.1 :1!9.0 37.1 11.4 
(1.53) (1. 56) - (16.14) (1.11) (23.02) <4.33) I {2. 64) 
(30) 9 117.5 44.7 281.2 18.3 381.6 50.3* 217.4 31.3* 25.3 
(3.30) (3.33) (10. 95) (O. 62) (38.25) (5. 66) (3. 50) 
a 
(90) 9 36.7** 253.6 18.1 353.e** 9* I & 32,7* 22.0 110.6 47. yl (3.28) . (3.24) (17. 06) (1. ~0) . (19.55) (3.00) (2. 40) 
Adrenalectomi~ed L (0) 12 114.8 23.8 428.0 
---
332.5 . 56.0 40.8 
(1.23) (1.76) (19.26) (25.58) (5.08) '(3.98) 
(10) 12 116.0 19.7 412.5 
---
272.1 57.2 -'2.1 42.4 -3.9 
(1.15) (1. 63) (21. 74) (21.84) (4.34) (3.28) 
(30) 12 117.3 22.9 399.5 
---
338.3 45.4* 18.9 33,0 19.0 
(1.11) (3.41) (18.08) (18.55) (3.03) (2. 46) 
(90) 10 117.3 1o.o*** 34s.s** 
---
311.2 37.3**3 3.4 29.3* 28.2 (1.63) (2. 64) (15. 94) {31.21) (3. 31) (2. 73) 
...!::.. Figures with:i.n parentheses indicate standard orrors of the means. I 
-t::' 
.£.:_ *• **,and*** indicate ~(.05, ~(.01 and E.<.OOJ..respectively. For al:.L other values, ()) 
~ ).05. 
,lnrJIT,m::r.J- .llln.;mi:IJ.- . tn:11i,ll .. rlli.J,;I .. ~: I ... :J, ~--· ·I, 1 ]J. 1] .. :·:·:~:~: i : .• :Jmp lllll: .. :::::::ipl!·!l·'. 1 .. 1.1: II r: 
are much greater then in the j_ntact control rats. 
Indomethacin produced an almost identical granuloma 
inhibition in adrenalectomized as compared to intact 
animals. 
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Phenylbutazone (Table VIII) effected some decrease 
in body weight gain ~ith little effect upon thymus or 
adrenal weights. There was a dose-related decrease in 
wet and dry granuloma weights and mg/100 g dry granuloma 
formation. After adrenalectomy, phenylbutazone signifi-
cantly decreased body weight gain ana. thymus weight at the 
90 mg/kg/day dose. It should be noted that the effective 
doses changed from 10 and 30 mg/kg/d.ay in intact ra-t;s to 
30 and 90 mg/kg/day in adrenalectomized animals indicating 
some loss· of phenylbutazone's potency with removal of the 
adrenals,. 
·:IJ.'he results of the sedative and ataractic reference 
standards are presented in Tables IX-XI.. Phenobarbital at 
10, 30, and 90 mg/kg/day caused a significant increase in 
body weight gain with no consistently significant effects 
upon thymus, adrenal, and wet or dry granuloma weights. 
These closes produced: no sedation, mild sedation, and 
heavy sedation, respectively. In intact animals, chlor-. · 
promazine (5,15, and 45 mg/kg/day) effectea. dose-related 
and statistically sig,nificant (lecreases in body an<.l thymus 
weights with a concomitant increase in adrenal \'!eights at 
the two higher doses. There was a dose-correlated decrease 
in wet and dry granuloma weights. Although chlorpromazine 
-
\: 
Tabie IX ~·- Effect of orally aclministered sodium 
phenobarbital upon cotton pellet 
granuloma formation. 
The mg/kg dosage is expressed as the salt. 
Treatment 
(mg/kg/<;lay) 
N 
(0) . 9 
(10) 9 
(30) 10 
'(90) 10 
Initial 
wt., g 
120.5 
~ (2.16)::_ 
117.8 
(2 .19) 
111.~* 
(1. 62) 
117.1 
(2. 74) 
Body Thymus Adrenal 
g 
wt. gain, mg/100g mg/100g Wet mg 
Non-adrenalectomized 
33.4 
(2. 09) 
325.0 
(14. 52) 
44. 3**~ 2s2 .4 
(1. 79) (22. 78) 
4o.s* 
(2 .45) 
** 41.8 
(1,78) 
248.1** 
(16.54) 
295.3 
(16.19) 
18.5 
(0,'69) 
18.3 
(1. 05) 
19.7 
(1.56) 
17.8 
(1.24) 
273.3 
(13,34} 
283.3 
(11.36) 
254.3 
(16.9Zio) 
266.4 
(13.16) 
Granuloma 
Dry mg 
38.8 
(2. 69) 
jwt. 
!;u 
I 
1 
42 . 7 -1![). 0 
(2. 49) 
37.4 31.6 
(3.01) 
. 37.5 31.3 
(1. 93) 
Dry 
mg/100g 
25.6 
(2.13) 
%I 
26.5 -3.5 
(1.56) 
24.9 
(2. 37) 
.23, 7 
(1.13) 
2.7 
7.4 
a. Figures within parentheses indicate the standard errors of,the means. I 
15'. *• **, and *** indicate P (.05, P (.01 and P (.001, respectively. For al!l pther values, 
~-).05. - - -
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Table X -- Effect of orally administered 
chlo:r.•promazine hydrochloride upon 
cotton pellet granuloma formation .. 
!~.'he .mg/kg dosage is expressed as the salt., 
'i'reatment 
(mg/kg/day) 
N 
(O) 10 
"(5) 10 
(15) 10 
(45) 9 
(O) 12 
(5)- '12 
(15) 7 
Initial 
wt., g 
117.4 
(1. 72)~ 
114.3 
(2.05) 
114.3 
(1. 42) 
115.9 
(1..27) 
114.7 
(2 .21) 
11!'.6 
(1. 82) 
111.4 
(2. 35) 
Body Thymus 
wt. ga~n. mg/lOOg 
g 
Adre:ts.l 
mg/100g Wet mg 
Non-adrenalectomized 
38.0 
(1. 07) 
34.8 
(1.. 75) 
284.8 
(12. 61) 
294.3 
(12. SO) 
**b . * 27.4 - 247.8 
(3.15) (11. 86} 
15.1*** 
(4.12) 
158.7*** 
(21. 33) 
18.0 
(O. BO) 
18.2 
(O. 99) 
20.0 
(0. 98) 
21.6** 
(O. 94) 
290.7 
(13.12) 
253.0 
(12. 93) 
211.s*** 
(11.03) 
192. 0 *** 
(5. 02) 
Granuloma.lwt. 
Dry mg I%! 
40.6 I __ _ 
(2.09) 
36.9 
(2. 51) 
32.4* 
(2. 60) 
r·' 
:20.2 
24:3* '10.2 
(2.00) 1 
A~renalectomized I 
25.2 364.1 --- 371.1 58.5 ---
(2.17) (13.32) (24.62) (4.03) I 
18.0 370.8 --- 299.2* 43.~* 25.0 
(3.82) (18.06) (9.13) (1.52) I 
*** * ** 9.8 361.2 --- 292.3 45.4 22.4 
(3.40) (26.62) (ls.so> (2.26) 1 
Dry 
mg/lOOg 
26.3 
(1.54) 
24.8 
(1. 78) 
22.7 
(1. 59) 
19.o** 
(1. 31) 
41.7 
(2. 84) 
34.2* 
(1.61) 
35.7 
(1.86) 
%I 
5.7 
13.7 
27.8 
18.0 
14.4 
a. Figures within 
~. *, **, and *** 
p ).05 .. 
~arentheses indicate the standard errors of the means. I 
:~.ndicate P (.05, E (.01 and g (.001, respectively. For a111 other values, 
mr~~:,~~~ .-.:lrltfl!lfl·, I , 11- -~~w11 .·urrl .. ll :11 I i I I! ":'1 I: 111'111'1 mm. i I .I, 
'v'l 
\>1 
I 
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Table XI -- }~ffect of orally administereo. reserpine 
upon cotton pellet granuloma forri1ation .. 
Treatment 
(mg/kg/day) 
N 
(0) 10 
(1.5) 10 
(4. 5) 10 
Initial 
wt.,g. 
117.4 
(1.72)_! 
117.2 
(1;83) 
116.3 
(1.78) 
Body Thymus 
wt. gain, mg/lOOg 
g 
Adrenal 
m~/lOOg Wet mg 
Non-adrenalectomized 
38.0 284.8 18.0 290.7 
(1.07) (12. 61) (O. 80) {13.12) 
28. 9**~ 324.2 18.0 234.s** 
(2. 63) (15.04) (0. 84) (8. 92) 
6.1*** 237.5* 24.5*** 194.2*** 
(4.18) (13.47) (1,20) (13.21) 
Granulo~La wt. 
Dry mg I %I 
40.6/ ---
(2. 09) 
35.5112.6 
(2. 39i) 
I 26~6t 34.5 
(3. 031) 
_! 
Dry 
mg/lOOg 
26.3 
(1.54) 
24.4 
(1. 65) 
21.6* 
(2.16) 
Adr&naleetomized ~ 
(0) 10 101.6 12.2 359.9 --- 332.0 48.9 --- 43.6 
(0.~9) (3.48) (?3.36) (24.13) (3.71) (3.91) 
(0.5) 8 102.5 11.0 35'8.8 --- 279.7· 41.8 14.5 37.2 
(1.84) (1.7:) (23.48) (21.25) (4.3·r (4.40) 
(1.5) 10 103.4 3.0 385.5 --- 276.3 42.'i: 12.7 40.4 
(1.13) (3.32) (18.27) (25.90) (4.68) (4.64) 
I 
%1 
7.2 
21.6 
14.7 
7.3 
a. Figures within parentheses indicate the standard errors of the meanJ 
'5. *, **, and*** indicate P (.05, P (.01 and P (.OOt,respectively. Fo~~ all other values, P).os. - - -
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seemed to lose some of its anti-inflammatory action "trith 
the mg/lOO,g conversion, it still retained significant 
inhibitory properties at the highest dosage level. It 
should be noted, however, that all of the doses utilized 
produced noticeable sedation, with the 1~5 mg/kg/day 
animals being almost non-ambulatory and exhibiting severe 
autonomic and extrapyramidal stimulation. In ad.renalecto-
mized. animals, chlorpromazine retained the same profile of 
actions excepting that t;here \'las no thymus involution. 
This compound still exhibited inhibitory effects upon 
granuloma formation although the 15 and 1~5 mg/kg/day doses 
killed [l.Q and 100% o:r the test animals, respectively. 
Reserpine (1.5-4.5 mg/kg/day) caused a severe 
dec~rease in \'Ieight gain along ~rd th significant thymus 
invoh:rtb·m and adrenal hype~ctrophy. The:c·e wer'e dose-
related .inhibitions of wet and cl.ry granuloma formation 
as \'1011 a.s heavy sedation a.nd a distinct reserpine-like 
syndrome·(blepharoptosis, miosis, hypothermia, hunched 
56 
back, etc.) at all of the doses tested.. Reserpine was 
e:Artremely toxic in adrenalectomizec1 animals and the highest 
dose that could be tested was 1. 5 mg/kg/day. Reser·pine pro-
duced similar trends of action in the surgically altered 
rats although the only statistically significant result \>las 
a decrease. in body weight gain~ 
As seen in Table XII, tetrabenazine (15 and 45 mg/ 
kg/day) produced effects similar to .those caused by reserpine 
(a mean clecre[lSe irr body 1.Neight; gain' of 15 g associated with 
-~ 
I~ 
rl 
Table XII -- Effect of orally a<1ministerea. 
tetrabenazine upon cotton pellet 
granuloma formation~ 
Treatment Initial 
(mg/ltg/day) wt. g 
N 
(0) - 10 
(15) 10 
(45) . 10 
135.4 
(3.19)~ 
139.7 
(2. 85) 
142.1 
(2. 92) 
·Body Thymus 
wt. gain, mg/100g 
g 
Adrenal 
mg/10Gg 
wet mg 
Non-adrenalectomized 
38.1 
(1.97) 
28. 3*-E 
(.3. 41) 
23.4** 
(3. 57) 
257.5 
(11. 40) 
18.4 
(1. 02) 
*** 187.2 18.9 
(10.64) (0.95) 
169.7*** 21.3 
(8."98) (0.51) 
279.0 
(10.03) 
266.2 
(17.24) 
221. 7*** 
(6.80) 
Granulom\~ wt. 
Dry mg I %I 
45.0 
(2.27) 
'i'* 3S.u 115.6 
(3.20) 
Dry 
mg/100g 
26.3 
(1. 32) 
'.ti 
22.s** 14.4 
(1.66) 
:t•• 18.~ 28.5 
(1.23) 
*** 30.7 131,8 (1. 54) 
------------------~--------------------------~--------- ,:---------------
(0) 12 
{2. 5) 12 
(7. 5) 5 
114.8 
(1.23) 
114.2 
{1. 19) 
120.8 
(4.28) 
23.8 
(1. 76) 
18.6 
{2. 06) 
4.4** 
(5. 95) 
Adrenalectorolzed 
428.0 
(19.26) 
395.7 
(15.70) 
351.7** 
(11. 53) 
332.5 
(25. 58) 
327.4 
(24. 75) 
311.4 
(20. 75) 
56.0 
(5.08) 
53.1 15.2 
(3. 02) 
47.3 115.5 
(5.41) 
40.8 
(3.98) 
40.3 
(2. 58) 
37.3 
(3.09) 
1.2 
8,6 
a. Figures within parentheses indicate the standard errors of the means. I 
'b. *, **, and**-* indicate P (.05, P (.01 anci. P.(.OOl, respectively, For a.ll other va).ues, 
- .E ).05. - - - ' 
. :. I, -lnJifH.-.J:IIUI;I. a: ,j., . I .. IJ, .1~1:.: ! ::.:::IWP-IIIIli.l ... lli:CHJ:ill[ll! I 1.1, .li i 
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thymus involution and adrenal hyperplasia). There was a 
dose-responsive inhibition of \vet and dry gra.nuloma forma-
tion. Increased toxicity in adrenalectomized animals was 
noted with the highest tolerable dose being 7.5 mg/kg/day. 
At these low dosage levels, tetrabenazine shmved only a 
non-significant inhibition of granuloma formation. There 
was also severe sedation and a reserpine-like syndrome at 
these doses. 
In Table XIII, it can be seen that RO Ll--1284 "ras 
59 
almost identical inits action to tetrabenazine. Decreases 
in body, thymus and granuloma weights were accompanied by 
an increase in adrenal weight. RO 4-1284 was the most toxic 
of all the compounds tested in adrenalectomized animals 
with only two animals surviving at 5 mg/kg/day. All animals 
receiving HO Lf .. ~.J.28lf. exhibited moderate to severe seclat;ion 
coupled \'lith a reserpine-like syndrome at the dose levels 
utilized.~ 
The effects of benzquinamide are sh0\1.711 in Table XIV. 
Doses of 60 and 180 mg/kg/day produced 13.1 and 23.196 inhi-
bitions of dry granuloma ~tTeight with a loss of body \veight, 
t;hymus involution and an increase in adrenal weight seen at 
the higher dosage level.. Increased toxicity after ad.renalec-
tomy as seen with the other benzoquinolizines was also noted, 
but the 13 .. 496 inhib:Ltion of a.ry ·granuloma 11eight at 60 mg/kg/ 
day indicated that benzquinamide does retain activity after 
adrenalectomy.. Benzquinamia.e produced mild sedation at' 60 
mg/kg/cla;r with moderate. sedation and a slight reserpine-like 
;~ 
Table XIII •n~· Effect of orally administered RO 4-·128'~· 
upon cotton pellet granuloma formatio:..1 . ., 
Treatment Initial Body Thymus Adr<:>nal Granulom~, wt. 
(mg/kg/day) wt., g wt. gain, mg/lOOg mg/lOOg Wet mg nry mg %I Dry %I g 
mg/100g 
I 
N Non-adren;J.lectomized 
--
(0) 10 11.7.3 37.7 309.7 18.1 314.2 44.0 
---
28.5 
(1.32)a (1. 85) (8.91) (O. 79) (13.98) (2. 43) (1. 37) 
(15) 10 1:1.9;6 29. 3**.!?.' 234.o*** 1~.7 248.3** 35.~ 19.1 23.9* 18.1 
(2. 04) (1. 66) (9. 38) (0. 56) (13.35) (2 .26) (1. 43) 
(45) 19.s*** i42.8 *** *** 19s.o*** 2s~t* 143.0 . ~** 34.7 10 116.8 24.4 18. 
(2. 50) (2 .20) (11.02) (1. 01) (9. 44) (2.18) 1: (1.81) 
-· I 
Ad~enalectomized 
(0) 12 124.2 15.2 390.2 
---
436.0 72.4 ~--- 52.5 (O. 88) (3.47) (19.93) (38.84) (4.98) (4.16) 
. *** *** ** . 4* 19.0 (5) 2 124.0 -10.5 256.6 --- 301.9 49. 131.8 42.5 
(4.24) (3.89) (6.22) (38.01) (ll.OO)i (6.65) 
~· Figures within parentheses indicate the standard errors of the means. I 
Q.. *•. **,and*** inc).icate_? (.05, ~ (.01 and g( .OOl,respectively. For a .• ll other values, 
.£ ).05. . 
11: I~-- llf.llf,ll...l:JI!:mt: L.l ;J, 1- •. I .. Jl, lli .ill~.i ~::)~fl.!l]li:~U.Jl:::..i;I.] . .J:Ij;f] ... i .. 1.. i.l· 
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Table XIV -- Effect of orally ad.ministerea . 
.. 
benzquina.mide upon cotton_pellet 
granuloma formation~ 
.• 
Treatment Initial 
(mg/kg/day) wt.g 
(O) 
(60) 
(180) 
(0) 
(20) 
(60) 
N 
10 
10 
10 
11 
11 
11 
122.8 
(1. 37)~ 
120.6 
(1. 67) 
119.7 
(2 .10) 
117.8 
(1. 18) 
118.5 
(0. 88) 
118.4 
(1. 37) 
a. Figures within 
Body Thymus 
wt. gain, mg/lOOg 
g 
Adrenal 
mg/100g Wet mg 
Non-adrenalectomized 
30.2 
(2. 06) 
25.4 
'(1.74) 
11. g*** 
(1. 74) 
21.8 
(2. 31) 
15.0 
(2. 61) 
16.3* 
(3. 55) 
263.5 
(13.04) 
22s.1 *£ 
(10.03) 
***· 138.0 
(13. 83)" 
19.0 
(1.15) 
18.0 
-(1.62). 
*** 26.3 
(1. 42) 
338.7 
(23.14) 
339.6 
(19.58) 
*** 177.7 
(21. 42) 
Adrenalectomized 
368.9 
(12. 63) 
402.2. 
(17.58) 
332.6 
(15.16) 
383.4 
(29.18) 
383.6 
(27. 30) 
349.9 
(12. 70) 
Granulomalwt. 
Dry mg I%I 
49.0 
(3.61) 
40.2 18.0 
. (2.55) I 
"'** 31.3 ::t6.1 
(2.07) ·1 . 
65.9 L 
(4. 87) I 
63.0 ~t. 4 
(5. 55) I 
59.2 10.2 
(3.21) 1 
Dry 
mg/100g 
32.0 
(2. 32) 
27.8 
(1.98) 
24.6* 
(1.75) 
47.6 
(4. 06) 
47.2 
(4.44) 
41.2 
(1. 84) 
%I 
13.1 
23.1· 
0,8 
13.4 
b. *• **, and *** 
- p ).05. 
parentheses indicate. tlle star;<lard erro:::s of the means. I 
indicate E, (.05, E, (.01 and~ -(.001, respectively. For aJ,Ll other values, 
IIP.ItniJJI; 1.11 1. •• • ,·. 1 1 .1n~1~11: .. r.'ll.ll~l:. , •.. :1.· J ! .. !l Jli ,,, .llJ:,,' I ;;_,,"~~fl. l!FJ..l.i.J:::.; 1f llil]:fj: .. l' : •• i _/,' H: 
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synclrome at 180 mg/kg/day. 
HO 1-956/t-, as shown in Table XV, effected 12.3, 
24.2, and 33.3% inhibition of dry granuloma formation with 
no effect upon body weight gain or adrenal weights. There 
was a slight, but significant, decrease in thymus weights. 
RO 1-9564 retained full anti-inflammatory activity in 
adrenalectomized animals, and without the increase in 
toxicity noted for the other benzoquinolizines. Upon gross 
exaritination, the rats exhibited no signs of sedation or any 
autonomic manifestations. 
Slightly higher rloses of cryogenine than those pre-
viously used to document its anti-inflammatory capability 
were needed to inhibit granuloma formation$ As :reported in 
Table XVI, doses of 63 and 189 mg/kg/day decreased. granuloma 
weights by 11 .. 6 and 28 .. 896., There were also losses in body 
weight, thymus involution and adrenal hypertrophy at these 
dosage. levels.. Cryogenine appeared to bf-) relatively inactive 
in adrenalectomized animals. 
2.SJ..E.E§E.<2.~in ;i.T}_?,.u..22i E2cl.a}.~d.em,?;_ 
A time course stud.y of carrageenin-induced edema 
(F'ig., 5) shOitJed a very sharp rise :Ln edema formation up to 
1.,5 h after subplantar injection., The amount of edema· 
stabilized approximately 2 h after injection and \'las main-
ta:Lnefi up through + 5 h -·- after \'lhich time the p<:n.r volumes 
began to ctiminish in size .. 
'I'he effects of tetrabenazine upon the early and 
late stages of ec1ema formation after subplantar carrap;eenin 
"-'-
Ta.ble XV -·D Effect of orally adrn:iniste:red RO 1-9564 
upon cotton pellet granuloma i'o:r.ma.tion~ 
II~ II:, .. 1. , I" I· 
Treatment I:1itial Body Thymus Adrenal Granuloma lwt. 
(mg/kg/day) wt..l g wt. gaia, mg/100g mg/lOOg Jl<st lUg Dry mg 1%! Dry %I g 
mg/100g 
N Non-adrenaloctQmized ~--(0) 10 117,3 37.7 309,7 18.1 314.2 44.0 28.5 (1. 32)= (1.85) (8. 91) (O. 78) (13.98) (2. 43) (1. 37) 
(10) 10 117.0 36,3 *b 280,3 - 19,5 263.7* 38.5 l!2. 5 25.0 12.3 
(2. 37) (1.41) (8. 97) (0. 98) (16.12) (2. 75) (1. 52) 
(30) 10 116.6 33.0 269.7** 18.3 247.9** 32-:'i* 2 7.0 21. 5** 24.2 
(1. 45) (1. 99) (12.88) (0.69) (14. 52) (2 .19) (1. 60) 
(90) 10 119.9. 34.2 259.7* 17.2 221.1*** *~* 19.o** 33.3 29. 313.6 (1. 54) (1. 70) (15.00) (0.89) (11.16) (1. 76) (1.19) 
Adrer.alectcroized 1_ 
. (0). 11 117.8 21.8 368.9 
---
383.4 65.9 47.6 
(1.18) (2. 31) (12. 63) (29.18) (4. 87) (4.06) 
(10) 11 119.3 21.8 336.1· 
---
368.7 53.8* 18.4 37,9 20.4 
(1. 34) (2. 92) (13 .28) (31.49) (s.is: -I· _ .. (3.23) 
(30) u 114.6 21.9 397.0 351.4 
---
53.7 18.5 39,5 17;1 
(1. 04) (1. 57) (16. 69) (21.14) (2.78: I . (2.17) 
(90) 12 117.5 25.8 372.7 
---
356.3 47.1 28.4 33.1 29.8 
(1.22) (2. 89) (14. 64) (23. 62} (4.20) 1 (3.13) 
a. Figures within parentheses indicate the standa:.::-d errors o:f the me~lns. ()) h. *· **· *** indicate~ (.05, ~<.Oland E_ (..OOl,respectively. For ~11 other ()"\ 
values _;e_ ).05. 
ln:JII.ll .. l.ill.li!L",.J :Ji I .. I J • i ~ !;' 1 : ... ::~mp 11!11 .. L.:.Jr. :. ; ll 1 ]dJ:[j I ... ·; .• I I, li , [:: 
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'rab.le XVI ··- Effect of' orally admi.nistered cryogenine 
upon co~;ton pelle-t granuloma formation. .. 
Body 'l'hymus Adrenal Granuloma/-wt. "Treatment Initial 
{mg/kg/day) wt ., g wt. gain, mg/lOOg mg/lOOg 
g Wet mg Dry 
mg/100g. 
%I ----~-----------------------------------------------------D-r-y-mg.~~-%-~------------
(0) 
(63) 
{189) 
(0) 
N 
10 
10 
10 
11 
(63) 12 
(189) 7 
Non-adrenalectomized 
125.5 38.2 
(2.51)l!.., (2.51) 
123,9 
(2. 16) 
126.8 
·. (1. 92) 
34,7 
(1.66) 
18 ..t*** 
<2. is> 
343.9 
(18.02) 
262. s**l? 
(15.89) 
243.s*** 
(8.12) 
16.2 
(0. 91) 
18.5 
(O. 72) 
21. g** 
(1,:)7) 
333.4 
(20. 'i"5) 
292.7 
(17.12) 
234.s*** 
(15. 57) 
Adrenalectomized 
125.9 
(1. 37) 
129.2 
(L40) 
128.5 
(1.78) 
13.7 
(3. 94) 
364.2 
(14.24) 
14.6 354.5 
(4.14) (15. 84) 
-s.o** sss.3 
(3. 88) (13. 64) 
399.5 
(30.42) 
349.3 
(16. 46) 
313.8 
(29. 55) 
49.2 
(3. 67) 
"' 42.0 /14.5 
(3. 02) 
. s1.~"''rss.s 
(2.35) I 
60.6 
(4.10) 
57.3 I 5.4 
(3. 31) 
49.4 I 18.5 
(6.35) 
30.2 
(2. 45) 
v" 
26.7 
(2. 06) 
21. s** 
(1.70) 
43.8 
(3.36) 
40.0 
(2 .08) 
40.8 
(5. 85) 
a. Figures within oarentheses indicate stand~~d erro~s of the means. 
b. *, **, and*** indlcate _£ (.05, R (.01 and-~ (.OC1,respectively. For /all other values, 
.£ ).05. 
11, :.·1·1 ~-tn.liJ;J-I .. JJIL!Ill.:' ;[; 
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Fig .. 5 -- Variation with time of pedal ec1ema 
induced by subplantar injection of 
0.1 ml of 1% aqueous carrageenin .. 
0 Indicates mean of 10 rats, 
brackets indicate standard errors. 
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in;jec.tion are outlined in .Table XVII., At closes of 5, 15, 
and Lf-5 mg/kg, t·etrabenazine blocked: the eat•ly stage of 
edema up to 9696 with a significance level· of ,r. ( 0 .. 001 at 
all doses tested.. There was less of a c1rug effect upon 
the latter st:age of ed.ema -- but· all inhibitions were sig-
nificant at a confidence level of .r. ( 0.05. 
RO Li--128Lf. inhibited edema forma.tion 15 .. 4, 50.0, and 
69 .. 296 at + 30 min \·dth the t\'JO higher dosage effects being 
statistically significant.. This compound had. a more dra·~ 
matic effect upon the 3 h edema formation than did 
tet:ea.benazine -- with inhibitions up to 54-96 and. statistical 
significance at all d.osage levels., 
Bem.:>.quinamide, \'-lhich v.ra~J the leEJ.st potent ag(~nt; :i.n 
the 0otton pl~Jlet granulor.nr:t assays~ inhibited the earl;,.,. 
stages of~ pedal ed.ema up to ~!95G but ac-tually increased edema 
formation at the+ 3 htime interval .. 
As seen in Table XX, RO l-956LJ. significantly inhibited. 
edema formation in both the early and late stages up to 92 .. 9 
and 38 .. 3%, respectively. This inhibition \'-las not accompanied 
by overt sedation or by any autonomic manifestai;ions. 
Table XXI outlines the effects of cryogenine upon 
cax·rageenin eclema in both intact and adrenalectomized rats. 
Cryogenine (100 mg/kg) significantly inhibited the 
early ancl late phase s\\relling by 31.0 ana. 63 .. 0%, respectively. 
In adrenalectomized animals, cryogen.ine hacl little effect 
upon the early _stage of edema formation but did significantly 
decrease the late-stage swelling by 25 .. 2% ... 
,_ 
F 
Table XVII -·- Effect of orally· administered 
tetrabenazine upon carrageenir..·., 
.induced pedal edema. 
~ ~ '-:.· 
Drug 
treatment 
(mg/kg) 
... Control 
. .;.: . (0) 
Tetrabenazine 
. ~5). 
(15) 
(45) 
N 
9 
9 
9 
9 
30 min 
0.26 
co.o4)a 
o.oG***b 
(0 .'03) -
o.o3*** 
(0. 02) 
o.o1*** 
(0. 02) 
a. Figures within parenthese indicate the 
b. *, **, and *** indicate P (..05, P {.Ol 
V3~lues P )'. 05. · 
~· ~ ~ f 1._ • mean m.l· ea.ema · orma·lt-lO!l 
%I sj h %I 
. ~---
p. 92 
({).05) 
* 0.73 76.9 (b.06) 
I· * 0.79 ss.s cb.os> 
I ** 0.62 96.2 (b.06) 
I 
I 
stand8.rd errors of the m.e:1ns. 
. I 
and!: (.OOl,respectiyely. For 
20.6 
14.1 
32.6 
all other 
-....J 
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1l1ahle XVIII -- Effect of orally administered 
RO ~~-1284 upon ~arrageenin= 
induced pedal edema. 
Drug 
treatment 
(mg/kg) 
Control· 
(0) 
N 
9 
30 min 
0.26 
(0.04)!!:, 
Mean ml. edema 
%I 
f l- . orma~1on 
31 h 
I . 
p.92 
(p.p5) 
%I 
RO 4-1248 I **b · (5) 9 0.30 -15.4 p.68 - 26.1 (o:os) · (o.os) 
* I *** (15) 9 0.13 50.0 p.42 54.3 
(0.03) (1.02) 
** *** (45) 9 0.08. 69.2 p.-4.8 47.8 
(0.04) . (10.04) 
"i 
a. Figures within oarenthese indicate th~ standard errors of the means. 
b. *, **, and *** ~ndicate P (.05, P (.01 and P (.001,respecti~ely. For all other 
values ~ ). 05. - - -
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:P.able XIX -~· Ef.fect of orally s.clmininterco. 
b0nzquinamide upon carrageenin-
induced peds.l edema .. 
Drug 
treatment 
(mg/kg) N 
Mean ml edema forma·fion 
30 min %I 31 h 
------- I 
0 60 
Control 
(0) 9 Oo.42 
(0.04)a 
Benzquinamide 
(20) 
(60} 
9 
9 
0._33 
(0. 02) 
*b 0.32 -
(0. 04) 
21.4. 
23.8 
I • (p. 04) 
p.78 (p. 08) 
'0.69 
c5. o4) 
%I 
-30.0 
-15.0 
( ) ** I 1so 9 0.30 28.6 e-72 -20.0 
(0. 01) (10. 06) 
a. Figures within parentheses indicate .the standard errors ofjthe means. . 
b. *, **, and *** indicate P (.05, P (.01 and P (.OOl,respect~yely. For all other 
values P ).05. 
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'l'able X'.l --· Effect of orally ad.ministerec1. 
Ro ~ a~r,, .. ..1.·~ ,..:;o-1· upon cc.rrageen:tn-· 
induced pedal edema •. 
Drug Mean ml edema for:m,.tion 
treatment 
(mg/kg) N 30 min %I 3; h %I 
- 1. 
I 
Control 
(0) 9 10.42 
---
IO. 60 
(0. 04)a ~0. 04) 
-
I 
RO 1-9564 
o·og***b (10) 9 78.6 IO. 60 o.oo ' . (0. 04) QO. 07) 
(30) 9 0.11*** 73.8 <16* 0. ~ 23.3 
(0. 02) QO. 05) 
(90) 9 o.o3*** 92.9 0.37 ** 38.3 
(O. 03) f·05) 
a. Figures within parent.hese indicate the standard errors of ~;he means. 
b. *, **, and *** indicat~ P (.05, P (.01 and P (.OOl,respectJvely. For all other 
values P (.05. 
-.._J 
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'11a.ble XXI -·- E:l'reet of orally administered cryogenine 
upon cG.rrageenin···induced pedal edema in 
intact and adrenalectomized rats .. 
Drug 
treatment 
(mg/kg) 
Control 
intact 
Control 
adrenalectomized c. 
Cryogenine 
intact 
(100) 
Cryogenine 
adrenalectomized 
(100) 
N 3Cf mj.11. 
10 0. 42 
(0.04)~. 
10 0.34 
(0~03) 
9 0.29*b 
(0. 04) 
9 0.32 
(0. 04) 
Mean ml edema formJ.tion 
I 
%T ~ h c~ i £. 
31.0 
5.9 
1.00 
~:0.06) 
1.07 
(0. 03) 
0. 37***· 
(0. 04) 
0.80 ** 
,, ) 1,0. 08 
I . 
a. Figures within parentheses indicate the standard errors oflthe means. 
%I 
63.0 
25.2 
b. *, **, and*** indicate P (.05, P (.01 and P (.001,respect:Lvely. For all other 
values P) .05. - - - 1 • 
- . 
c •. Animals adrenalectomized 10 days prio~ to the day of assay land maintained on 0.9% 
saline. · 
()) 
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DISCUSSION 
As discussed previously, inflammation seems to be 
a relativel:yr specific response initiated by a ·vari(:;ty of 
non-specific physical, mechanical, chemical 9 or imnrunologi-
cal mearl.s.. F'or this reason, many dis-similar types of 
t;hat certain of' the results will corro1ate with clinical 
anti-:Lnf1amrnator;y activity.. Hovvever" it; has been shO\'.Jn 
that: moGt of the experim•.:mtally~<Lnduced inflamrn'::l.ti.onB a:ce 
suscept;ible to inhibition by :cather non·-selective d:cugs or 
that: conflicting ro::n:t1ts can be producec1 with slight changC'~G 
exudative models of inflammation are particularly prone to 
yield falsc~-positive results for atypical agents and to be 
depend(~nt upon rigidly control lea. experimental conditions 
for• consistent results., 
r1any su.bstanees have been used as phlogistic agents 
to produce inflammation in the paws of' rats.. Edema produced 
by purE: chemical eompounds (some suspected to be mediators 
of t;he inflammatory response) such as serotonin, histamine, 
brad.ykinin and. compound lf.S/80 are inhibitea. by agents that 
are receptor antagonists for these compouno.s (antihistamines, 
etc.); hm·mver, these agents are not clinically effective 
anti-inflammatory agents. Less specific irritants such as 
82 
83 
yeast, formalin, eggvJhite, k~J.ol:i.n, dextran, and ca.rrageenin 
. are also inhibited by c1.iiiica.lly inactive agents.. .A com·-
parative study of edema :inhibition by both clinically ac·bive 
and antihumoral agents upon the various klnds of incluced-
ed.ema has been reported by \vinter (63).. His findings sug·-
gest thai.; of all the e:z,'V.clati ve models o.f inflammation 9 
carrageenin-induced pedal edema is the 1ea.st susceptible 
to non-·specific :Lnhibi ti.on., In ccmtrnst, .S:il vesti·ini (13) 
has summarized the data of other investigators to show that 
ca.rrageenin-·induced edema can be :i.nf1uenceo by- aty-pical 
ant:i-inflammator;:;,r agents such as morphine., chlorpromazine~ 
iproniazicl~. IBD-·25~ and chlo:rothi'a~~ide .. GD.rattini et a.l., 
·-.,, .__, ......... ,.~..-.. ~ 
( r:..fl.'; <:<i·na"-'L,-,•'1 ·i-l1L' s· e··1"'-·l·~ .. l."1"J·.: .. y o·r:" "Lr'"""l L•<iem•>e< ·1-o "-"yste1n1'c o.J1 10::.1 .J ..... • ~ V' v ..... -c-... .J i:)n.ll. \.!.~lt ~l .. iJV(....\- -..;,:.; __ ~ Cl • ..:t V\ '· )..) • 
.b.,... ...... t'~{"t ·] .• '"' 1 of'f'·, .. ..r.~·t•., , ... rl '·"··, ,.:' ] ... "~ .,.i .. .1/ ••• ,. 1" "l •' .• J . ....... J p .a.r:ffio ..... O ... OgJ.ca. ...,__ f.JC 0 .:~ 8.11, ... J. OlJ.llJ. Glld., 08.t:.r'df:/~f.Y)J .. I,·-J .. YJ.( .U~f:.L 
edema was inhibited by classical anti~:in:flammatory agents 
and not af:f:\~cted by changes in environmental c.ond:i.tions 
(1;eri!))erature c:md. humidity)., or hypothermia~ diuretics ancl 
hypotensive agents. Adrenalcwtomy or adrenal demedulJ.ation 
had no effect upon the d.evelopment of edema, but the 
administration o·r ACTH or hydrocortisone significantly 
inhibite(i. th.e formation.. ;rhis indicated that carrageenin-· 
induced edema was susceptible to the effects of agents that 
stimulate the release of end.ogenous corticonteroids.., 
Car:r.:aageenin-·induced. edema vm.s also inhibited by thf.: i:ntra-
peritoneal administration of general irritants suggegting 
that anti-inflammatory agents should be given orally in 
order to minimize this "coun-tori.:rrita.tion effect." 
Inhibition of edema by i.ntraperitoneal1y-ad.rninistered 
irritants \'las not dimi:nished by prc~1r:Lous adrenalectomy. 
It should be noted. that the disagreement o:f these 
various authors as to the susceptibility !:lf carrageenin-
induced ·e(lema to non~-Bpecdfic inhibition could be c1uo to 
dif.fe:r•ences in experimental technique., The atypical 
agents T."E)pm:-ted b;y SJ.litest:c.•ini. (13) \J\rere a.ll administered 
su.bcuta.noousl;y.,. and could. have caused countE.~rirrit:ation 
effects" lt :u.J generally agreed that the cmwlusion.s of 
EY+ 
Winter (6:5) are correct and that carragr~enin-indu.cr::!d pedal 
edema. is the most reliable exudative model in extrapolating 
experimEmtal O.a"t;a to clinical r:mti-in:f:'J.mma~:ory rlf'fectiY8TH'3SS .. 
Tn" .• b; t·i 0 Of ·· 'Y>•. 111 "I 0m .f'C . .,.., 0 •- • "11 ,. U c<~_,,~ 1 "I" ti·· · ..L~ • ..tll. _,_ ~-- n _ g ..... a U..L ..... a .... ..._m, .. :t;J.,) Cd -•~vv. D,1 _.te 
subeut"aneous implantation of cotton pellets is thought to 
be a much more selective test; for -(;b.(~ eva.lua·tion o:f:' drugs 
useful inthe treatment of' chronic inflammatory diseases 
(13) o This B.ssay is conside:I'ecl to measure an anti-
inflammatory agent's ability to interfere \'Vi t;h the prol if'-
erativc component of thE'; inflammatory proce~~s.. Both 
steroidal and non-steroidal anti-inflammatory agents inhibit 
the cotton pellet f_.~ranuloma (13).. vlinder (65) suggests that 
the test has less sensitivity for non-steroidal agents than 
for steroids& In contrast, vlinter (63) found the dose-
response curves fo:r.· both types of agents to have similar 
slopes., The formation of grf1nuloma is sub;ject to inhibition 
by the subcutaneous or intraperitoneal administration of' 
irritants (66) -- again stressing the necessit~r of oral drug 
administration.. Silvestrini (13) has :\::oeporte<l that cotton 
pellet granuloma formation is subject to inhibition by some 
non-selective and atypical agents, but: again these e.gents 
were administered subcutaneously and could have been irri·-
tating ... winter (63) does not consider a compound to be a 
true anti···inflammatory if it inhibits granuloma formation 
\IThile affeeting thymus 'i adrenal or body vmights upon oral 
administration --· thc~se metameters are very sensitive 
indicators of endogenous steroid_ release. Such release 
could be due to a direct drug effect upon the pituitary·-
ad:r.•enal axis or to a non-specific toxie st:ress phenomena., 
Px·el:i.minar;y studies i.n this laboratory hacl ind.:iea-t;od 
that man;y of the d.rugs to be UI:Fjd in the preBent r,.rtu<ly v;ouJ.O. 
affect bo(l;y 1:\7eigb:t ga.:i.J'). ana_ tb.e 'b.cmeoste.ti.c co:n:trol of 'I,•Tatel' 
balance'~< ~f.'herefore, it became of in:terest tc ~rf;u.dy the 
ef'f'eets of food deprivation, dehyd.:rat"ion, an.cl food a.epri-
vation +<1ehydration upon granuloma formation.. Table V 
indicate(l that for all of these treatments there w·ere sig-
nificant decreases in the absolute weights of the granulomas .. 
~Jhen converted to mg of granuloma weight/100 g of final body 
weight, the inhibitions became non-significant., These data 
are i.n agreement with the findings of Dipasquali and Melli 
(67).. These authors demonstrated similar effects for 
rest:r.·icted food intake for the enti~"e time period of granu--
loma format;ion.. Since intact rats were used in their study, 
adrenocortical stimulation in response to stress could not 
be e:.cclud.ed. as a mechanism for this granul9ma inhibition .. 
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In our stuc1.y, the collection o:f thymus and adrenal weights 
indicated that there was undoubtedly some steroid release 
under these conditions as· evidencecl by ao.ri.:mal hypertrophy 
and thymus involu-t·ion.. The data in Table VI indicated that 
hydrocor:t;isone caused a decrease. in. body and thymus weights 
along with significant inhibition of granuloma formation .. 
This inhibition remaineo. statistically significant after 
the mg/100 g body vmight conversion 'itJhich suggestNl that 
i.;he effeci.-;s of' hydrocortisone were not entirely due to a 
decrease in body weight.. Therefore, it would be expect eel 
that if the effects of food deprivation ana_ d.ehydration 
v1ere due solely to steroid release, the granuloma in,.~ibi-
ti:ons shou1d have remained atatistieaJ.ly s:Lgni:fieant aft<~r 
the mg/100 g conversion.. Another more~ likeJ.y possibility 
is that· inadequate nutrition or improper \•Tater balan.ce may 
directly impair gro-vrth and division of fibr.•oblasts in the 
proliferating granuloma ano. that this effect is directly 
related to the decrease in total bod.j7 weight.. Table VI 
also illustrated that corticosteroia.s effect a thymus 
involution similar to that described by a number of authors 
(68,69).. Exogenous aclininistraticm of hydrocortisone should 
decrease adrenal weight -·* the apparent increase in ac1renal 
weight; (not statistically significant) that was observea. 
may be attributed. to the fact that this was our first 
attempt at this type of anti-inflammatory assay and the 
technique for accurate removal of the adrenal tissue had 
not yet been pen•fected . ., 'J.'he inhibitions of dry granuloma 
-
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formation are :Ln accordance with results publiHhed by 
Winter (63) .. 
'l'he :r.esults obtained. for indomethacin treatment 
(Table VII) were similar to those obtained by other authors 
tG7.: r70 n·1) \ . . ) ' ~ ( -- .. The data indicated that indomethacin was not 
toxic j_n the anti-inflammatory dosage range ana. <lid not 
stimulate the release of en.d.ogenous corticosteroids" The 
complc-::te retention of anti-inflamma·!;ory capabilit;y aft(n:· 
adrenalectomy confirmed these findings.. Phenylbui;azone 
a.isplayed a similar profile of action with the exception 
of a decrease in bod.y weight at the higher dosage levels .. 
This inc'l ... ic<:,tecl some toxicity or endogenous steroid. release 
at the~~e <1oses.. In adrenalectomized rats~ phenylbutazone 
retaine(1 j.:l;s anti-inflammator;y properties but there seemecl 
to be some shifting of the dose--response curve with the 
lO'I.'lest il effecti'\re" dose becoming ineffective under these 
conditions., 'l'h:i.s could ind.icate that part of the anti-
inflammatory action of phenylbutazone may be mediatea. 
through the pituitary-adrenal axis.. other authors (16,72) 
have also noted this attenuation o.f action in adrenalecto-
mized animals., Bernauer and Schmidt (73) have demonstrated 
that phenylbutazone administered intramuscularly to rats 
in doses of 25-200 mg/kg ind.uced a dose-parallel depletion 
of corticosterone.. Domenjoz (16) has concluded that although 
the anti-inflanmtatory properties of phenylbutazone are prob-
ably not attributable to induced corticosteroid release, 
this effect could. account for some of the clinical side 
effects noted in humans. 
Inhibition of inflammation by drugs that have 
action$ upon the central nervous system is difficult to 
interpret.. Each of the many diverse effects of these 
agents (~ .. ,g .. hypot;hermia, analgesia, seo.ation~ central 
au·t;onomic regulation and release of trophic hor·mones from 
the pituitary gland) could. be considered. to contribute 
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to this phenomenon (16)., In most cases, these a.gentr.:: also 
have peripheral effects upon blood pressure, microc:LrcuJ.a-
tion and neurohumoral substances or receptors, as 'vell as 
upon metabolism.. The compounds used in the present study 
were mostly ataractics; therefore, sedation and dncreased. 
locomotor acti'l.rity were effects that should be apparent at 
high dosage levels. Sodium phenobarbital was utiliz.ed to 
assess·the effects of sedation upon granulation tissue 
formation.. 'Ylhen barbiturates are given in sedatiYe or 
hypnotic doses, direct ac·tions on peripheral structures 
are absent or negligible (1?).. There is little effect 
upon boa.y temperature, blood pressure or the autonomie 
nervous system.. They do not produce analgesia and may 
even effect hyperalgesia in lm'l/ closes (7L~). l'Jhenobarbital 
is a well tolerated barbiturate with one of the longest 
durations of action (10-12 h) (75) and should, therefore, 
be a useful model for the assessment of a sele~c·l;ive seda-
tive effect upon the inflammatory process. The results 
in Table IX indicated that phenobarbital (at lov1 to hi~h 
sed.ati ve closes) had no effect upon thymus, adrenal or 
granuloma "'eights.. The only stat:LsticaJ.ly significant 
ef'fect was an. incrHase in body weight.. Although no simi-
lar data could be found f'or the cotton pellet granuloma 
assay, phenobarbital (in doses up to 160 rng/kg) has beEm 
shown to be inactive in carrageenin-induced ec1ema (76) .. 
It can be coneluded from this data that sedation p~ 5:e is 
probably not responsible for the anti-inflamme:tory effects 
o:f central nervous sy·stem depressants. 
Chlorpr·omazine has been shOi"i!l prcjviously to be 
fj.nti-inf'lamm2.tory in a variety of experimental models· 
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such as carrageenin-· (13,1'+), formalin,~ (?7) and. serotonin."~ 
indue eel (7?) edemas.. Both Silvestrini (13) and Sax~~na (78) 
havo d.emonstrated tb.at parenterally-aclministered ch1o:rproma·~· 
z,:l.n~:~ is effective in inhibiting granuloma forma.tion.. The 
p.:ceBent; stu.dy confirmed this finding an6. also shovred ·that 
chlo:r:-promazine is ac-tive \•lhen administered OJ.:>al1y., 
The myriad of pharmacological effects proCl.uced by 
chlorpromazine make it extremely· difficult to prea.:Lct a 
l'Ossiblt~ mechanism of action for this compouncl.. TJ.1e nega-
tive res·ults obtained lJJ'i th the administration oJ.' pheno~ 
barbital i.nclicated that the central sedative component of 
chlorpromazine \'ras pi·obably not involved... Chang (79) sug-
gested that its antihistaminic, antiserotonin and anti·· 
brad.ykinin activities were not responsible for the inhibition 
of ca.rrageenin-induced. pedal edema since cyprophptadin.e (a 
more potent inhibitor of these substances) was relatively 
inactive. Arr:Lgoni-·I'1artc11i et g-1 .. (80) proposed that the 
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anti-inflammatory properties of chlo~cpromazine could be 
correla.ted,with its hypothermic activity., This hypothesis 
has been contested by Garattini et al, (64) who demonstrated 
that meprobamate did not inhibit edema formation caused by 
carrageenin, yeast, dextran or compound l.f-8/80 'l.vhen compared 
(at equal hypothermic closes) to chlorpromazine., '; 'I'he corti-
costeroid-releasing potential of chlorprom<:i.z:i.ne has been 
highl~\r d.ebated., Oiling et al., (81) and Mahlfoux .§:.t Ql .. (82) 
repo:r.•ted. that reserpine ana. chlorpromazine inh:i.bitea. ACTH 
release, 'ltlhile I\1aickel ~-t .aL. (83) indicated that these 
compoU11(1S caused a persistent release of ACTH and high 
plasma cm.:>ticwsterone levels.. More recently, "Bhattach:_>"ra 
and Ma:r:·lm (f34-) showed that a single dose of reserpine (5 
mg/l{g ~ , int:r~aperi toneally) or ch.lorpromazj_.rle (?.5 mg/kg, 
intraper·itoneally) would cause a prolonged ACIJ:Ir release,. 
Arrigoni~I~artelli et a~.. (14) demonstrated that ·t.he anti-· 
inflamme:cory properties of' chlorpromazine (in carrageenin-
edema) were not a.iminishod in adrena.lectom:Lzed animals .. 
Data in Table X supp(':lrted the conclusions of the latter 
authors :Ln that chlorpromazine (in closes above 15 mg/kg) 
caused a statistically significant thymus involution and 
adrenal hypertrophy. Although chlorpromazine exhibited an 
increase in toxicity in adrenalectomized animals, it 
retained anti-inflammatory activity in doses up to 15 mg/kg .. 
These results indicated that chlorpromazine does stimulate 
the pituitary-adrenal axis, but that its anti-inflammatory 
p:r."operties are not solely attributable to this phenomena. 
Chlorpromazine also caused a significant weight loss but 
retained anti-inflammatory activity after the mg/100 g 
conversion -- this fact suggests that the retardation of 
body grO\·rth is not the only mechanism of action.Arrigoni·H 
Martelli £i .§...!:.• (14) have suggested. that the anti-
inflammatory effects of chlorpromazine were clue to its 
involvement with catecholamine metabolism and ·t;his factor 
will be discussed in a later section., 
91 
Reserpine is ano·!;her ataractic agent that has dis-
played ubiquitous anti-inflammatory propertiE~s.. It has 
been shown to inhibit the inflammatory edema induced by 
dextran (85), egg (86,87) ancl chicken (88) albumin, 
formalin (89~90) ~ serotonin (91) 9 and carrageenin (1'-1·),. 
Bh::rb"l-; and SHnyal (91) demonst:ratec1 a complete inhibition 
of cott;on pellet granuloma formation b;y reserpine (2·0 mg/ 
kg/day., subcutaneously); hm•rever 'J these authors did not 
evaluate its effects upon body weight or activa.tion of the 
pitui tary·-adrenal axis... The experimen:!;al evidence that 
reserpine st:i.mulates the release of corticosteroids has 
been previously d.iscussed. The present study verified 
that reserpine (1.5-4.5 mg~cg/day, orally) does inhibit 
granuloma formation and that it also effects thymus involu-
tion, adrenal hypertrophy and a severe dimunition of body 
weight ga.in,. This corroborated the hypothesis that reserpine 
does activate the pituitary-adrenal axis (83,84,85). The 
increased toxicity of reserpine in aclrenalectomized animals 
(Table XI) makes interpretation of these results rather 
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difficult but reserpine did seem to retain and possibly 
., ' 
increase its anti-inflammatory activity under these con-· 
ditions., The retention of anti-·inflarnmatory activity after 
the mg/~00 g conversion and in adrenalectomized an:Lmals 
suggested that the rea.uction of granuloma grmqth is not <lue 
to loss of body \'might or to the release of endogenous 
corticosteroids., Reserpine has a similar pharmacological 
its possible mode· of action would be redu:nclant.. Reserpine <t 
in contrast to chlorpromazine, not only inhibits the uptake 
of catecholamines but also causes a severe depletion o±' 
serotonin and norepinephrine both in the m~ntral nervous 
S;5'Stem ana. in the periphery.. It should. be noted that for 
both reserpine and chlorpromazine., the dosage levels needed 
to effnet inhibition of the inflammatory.response far exceed 
their ata.raetic doses -- this would severely limit the clini-
cal usefulness of these agents in the treatment of inflamma-
tory diseases .. 
The benzoquinolizine derivatives \'..rere synthesized 
as non-indole ataractic agents and vJ'ere thought to pref'er·-
entially deplete central store of catecholamines and 
serotonin (4·0,92).. Detailed investigations of the pharma-
cological effects of some of these derivatives have been 
carried out.. The effects of tetrabenazine and RO L~-1284 
are qualitatively similar (93); therefore, they will be 
discussed as a single group~ . 
Tetrabenazine is approximately 1/10-1/20 and 
RO 4·-128'-f· approximately 1/5 as potent as reserp:ine in 
ability to lower the levels of monoamines :i..n the brain. 
Maximal depression of amines occurs more rapicl.ly and less 
completely after.administrati6n of these·agents, and dura-
tion of ~.ction is. shorter than '"ith reserpine. The 
benzoquinolizine-induced c1epression C)f amine levels is 
prevented by the administration of monoamine oxidase 
inhibitors (40).. IVIoreover, the sec1ative aetions are 
re~rersed by the inhibition of monoamine oxidase (l~O) and 
by the tricyclic antidepressants (94, 95). ~ehe effects of 
benzoquinolizines in altering monoamine content of peri-
pheral organs is generally less pronounced than in the 
brain., In rabbits and guinea pigs, relativ·ely h:i.gh doses 
of tetra:be:nazine did not cause a marked. decrease in platelet 
or intestinal serotonin.. The norepinephrine content of the 
heart was not depressed in rabbits, \"i'hereas in guinea pigs 
a 5096 deerease in norepinephrine content \vas observed (93) .. 
other workers have contested this selective central effect' 
upon amine levels.. \'lith histochemical flu.orescence tech-
niques'i tetrabenazine has been shown to have a depleting 
effect in the peripheral tissues of t'he rat and mouse (96)., 
The fluorescence of accumulated norepinephrine proximal to 
a ligation of the rat sciatic nerve disappeared 4 to 8 hr 
after the administration of tet;rabenazine (100 mg/kg) (97). 
Haggendahl (98) has shown significant depletion of 
noradrenaline, dopamine and serotcmin from peripheral tissues 
of the rat and rabbit with administration of tetrabenazine 
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(100 mg/kg) o 'retrabenaz:i.ne also has been shown. capable of 
depleting noradrenaline from the granules of the adrenal 
medulla (92, 99) and of Cl.epleting platelet .serotonin i~ ~r}J~E~. 
(92,100)., 'rhe present data (Table I) suggests that tetra-
benazine. does not.deplete norepinephrine or serotonin from 
rat hearts in dosages up to 50 mg/kg.. The depletion seen 
by Haggendahl could have been due to the higher dosage 
utilizeo... Tetrabenazine and RO 4-12814- have some influence 
upon the autonomic nervous system.. They caused miosis~ 
palprebal ptosis., hypothermia and lacrimation (101) and. 
these effects were counteracted by monoamine oxidase inhi·-
bition ('+0).. Both compounds were alrw capable of lo\!Jering 
blood pressure (93) and of decreasing the response to 
exogenously-administered norepinephrine (92~102) -- these 
responses m:•e usually indicative of a:IJ2ha-adrenolytic 
actions .. 
The scant experimental data available on the anti-
inflammatory effects of tetrabenazine have been previously 
mentioned.. The present experiments demonstrates that 
tetrabenazine and. RO Lf.·~l28l~ (Tables XII-XIII) posser3 pro-
liferative anti-inflammatory properties., These properties 
are similar to those of chlorpromazine and reserpine and 
are associated vlith (but not necessarily dependent upon) 
bod.y \tleight loss and the release of endogenous cortico-
steroids. Eechaute et al. (48) have demonstrated that 
tetrabenazine (50 mg/kg) is capable of stimulating cortico-
steroid release. The pharmacological propert_ies of 
-- --
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tetrabenazine and. RO 4--128'~· are similar to those of 
chlo:r.•promazine and reserpine and, therefore t their mecha-
nism of antic-inflammatory action may be the same.. In the 
present study, inhibition of granuloma formation "ras 
evid.ent only at doses that produced profound central 9 
hormonal and autonomic effects -- this, of course, limits 
the possibility of their use in clinical practice. 
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In 1962~ a new series of 2~hydroxy~benzoquinolizine 
derivatives vJas synthesized. This series contained com-
pounds v.rith Bedati ve action but which did not influence 
serotonin or norepinephrine levels within the brain (93)o 
Weissman and Finger (44) demonstrated that benzquinamid.e, 
at ataractic dosage levels (5 mg/kg? intraperitoneally) 9 
had no effect upon brain monoamiD.es in the rat (J At higher 
dosage levels (50 mg/kg), there was significant depletion 
or both serotonin and norepinephrine but to a lesser extent 
than that caused by reserpine or tetrabenaz:i.nec At this 
dosage level, rats exhibited a mild reserpine·wlike syndrome .. 
In monkeys, dosages up to 20 mg/kg (orally) o.f benzquinamide _) 
di.Cl 11ot alter t·l1e brair1 levels of monoamix1es. Invest:i.gations ~ 
by Scriabine et al. (45) showed that benzquinamide adminis-
tered to mice (up to 100 mg/kg, intravenously) and dogs 
(25 mg/kg, intravenously) had no effect upon brain amine 
levels. Haggendahl and Roos (103) demonstrated significant 
depletion of noradrenalin and dopamine in rabbits after the 
intravenous administration of 10 and 100 mg/kg of benzquin-
amide. \'Jatts et p.l .. (95) showed no c1imunition of cardiac 
.. 
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norepinephrine le'IJ'els in rats by ben:z;quinamide. (50 mrs/kg). 
Scriabine et al$ (45) and Kao.zielavm and Gumulka (104) found 
benzquinamide to possess marked .~2J2ha-adren.olyt:i.c properties 
in anesthetized cats and dogs~ 
rrhe prese1lt study suggests that benzquinamide is 
similar to its anti--inflammatory actions to tetrabenazine 
ancl HO 4-·128L~ (Table XIV).. \vith oral dosages up to 180 mg/kg, 
there was inhibition of granuloma formation \'lith concomitant 
adrenal stimulation and a slight reserpint'3·-like synd.rome at 
the highest dose. Adrenalectomy did not seem to reduce the 
anti-inflammatory actions of' this compound.. There· \AlaS a 
distinct quantitative difference between benzquinamide and. 
the le.tter compounds, but both. pharmacologic types displayed 
anti-infhunmatory effect~£ at o:r above the doses neecled to 
elicit seo.o:cion anJ. depletion of brain monoamines, 
There is 11ery little published data on the effects 
o:f RO 1-9564.. Pletsc,her et al. (46, 93) found slight seda-
tive effects for this compound at rather high dosage levels 
in miee (50-1.00 mg/kg, intraperitoneally) with no associated 
reserpine-like syndrome or depletion of brain monoamines .. 
Data in Table XV suggested that the anti-inflammatory effects 
· of RO 1-·9564 were qualitatively different from those of the 
other benzoquinoliz1nes. In oral dosages up to 90 mg/kg, 
there was a potent inhibition of granuloma formation and a 
.slight but significant thymus involution; moreoever, there 
was no significant effect upon body or adrenal weights. In 
adrenalectomized animals, RO 1-9564 did not display the 
-~--·---- - ~- - ---
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increased toxicity noted for the other benzoqui.noliz:Lnes 
. . 
and. it retained· full anti ...:inflammatory activity.. At the 
closage levels utilized, there \V'as no ob.;ious sedation noted .. 
The data for the cotton pellet gr<:-;.nu1oma assays 
indicated that there can be no correlation between sedation 
or brain amine depletion and ant:i.-inflammato:-r.•y activity 
since RO 1~·9564 (the least potent; in effecting sedation and 
without amine-depleting capability) \vas an active anti-
inflammatory agent.. Benzoquino1izine-inducec1 stimulation 
of the pitui·IJary-adrenal axis also does not appear to be 
correlated with anti-inflammatory activity since RO 1-9564-
inhibited granuloma grmvth in intact rats vd.thout apparent 
steroid. release and retained. full anti-inflammatory act:bd.ty 
in adrenalectomized animals. The other benzoquinol:i.?.inA 
agents a.lso appear.•ed to retain their anti-inflammatory 
activity in adrenalectomized animals.. While sedation, 
depletion of brain amines and corticosteroid release were 
side effects associated with the anti-inf1ammatory capacities 
o:f tetrabenazine, RO 4-1284 and benzquinamide, these factors 
cannot account for their anti-inflammatory mechanisms of 
action., The <lata obtained for chlorpromazine and reserpine 
. supported this hypothesis, in that both compounds effected 
inhibition of granuloma formation and were active in 
a<lrenalect;omized animals., Reserpine depleteCI_ brain and 
. peripheral organs of norepinephrine and serotonin \~rhile 
chlorpromazine only decreased the uptake of these amines .. 
The effects of cryogenine 9 in intact animals were 
-
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sim.i.lar to those of tetrabenazine, RO L~·-128lf. and 
benzquinamide .. ·Inhibition of granuloma growth Nas asso-
ciated with body weight loss') thymus-involution and 
adrenal hypertrophy.. Cryogen:Lne differed from the .lat;ter 
compounds in that· it lost most of its ability to suppress 
granuloma formation in acl.renalectomized animalso This 
data disagrees with that found by other vwrkers.. De Cato 
e:t §_1.1. (39) d.id not notice any histological changes in 
thymus 9 ad.renals or spleens aftE~r cryogenine administration 
to rats (100 mg/kg, orally) for 21 clays.. Jiowc-nrer, this 
experiment was conductecl with a very small number of animals 
due to a shortage of the alkaloid.. Kosersky (36) <lemon-
stratec1 that adjuvant-induced arthritis effected body weight 
loss~ thyrnus involution and adrenal hypertrophy and that 
cryogenine reversed rather than augmented these changes., 
l It is possible that the severe state of stress inducecl by 
the polyarthritis was capable of masking the steroid--
releasing potential of cryogenine or that cryogenine's 
ability to diminish the inflammatory stress causeo. by the 
adjuvant; treatment outweighed its inherent adrenal stimu-
latory actions. Gryogen1.ne also differed from the reserpine;.. 
like benzoquinolizines in that it did not deplete either 
brain or heart of serotonin or norepinephrine (Tables II-III) 
at dosages up to the LD50.. Also, cryogenine effects :Lnhibi-· 
tion of granuloma formation -vvi thout concomitant sedation or 
autonomic involvement. 
The susceptibility of carrageenin·-induced pedal 
,---; 
edema to inhibition by drugs seems to be depeno.ent upon 
the time interval at which the pa\<1 volumes are measured .. 
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A revie1..,r of the time~·courf.:\e studies. conducted on carrageenin-
induced. edema revealed a varied pattern of results \'Jhen 
documented by different investigators.. \vinter et Ql .. (63) 
no·!;ed a striking acceleration of edema formation 1-3 h after 
pec1a1 injection, '!Jith very Jii;t1e svle11ing during the first 
hour.. Van Arman (105) observed a rapid rise in edema for-
mat ion f:r.om zero· to + 2 h and no aclilitional edema formation 
after the first two hours.. Vinegar etM a1~ (106) indicateo. 
that carrageenin-induced edema progressed in t\vO phases.; 
The first phase was noted immediately after injection of 
the irritant and the rate of formation d.uring this phase 
diminishect within one hour., '.I:he second period of accel-
orated. cK1etm formation began shortly after the first hou:r 
anc1 persisted through the thiro. hour.. Concomitant \oJ"ith 
these tvm phases of edema formation \-'Tere two distinct 
stages of pedal hypertht::~rrnia.. When carrageenin \>laS charred 
by heat treatment, it produced only the full first phase of 
ec1ema ttlithout the second phase.. This indicated that the 
second. phase was not necessarily a consequence of ·the 
processes initiated during the first phaseo Vinegar (107) 
has previously shown that the edema follO\'Iing the subplantar 
injection of kaolin also develops in two stages.. The major 
portion of the first phase in both systems occurred within 
a half-hour after injection. This phase in both systems 
was inhibited by aspirin and epinephrine and was relatively 
" 
insensitive to hydrocortisone, chlorphenira.mine, 
cyproheptadine p.nd phenylbutazone •. The second phase 
oi' carrageenin-induced ea.ema -vms very sensitive to 
inhibition by the classical anti--inflammatory agents 
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such as 'hydrocortisone, ina.omethacin and phenylbutazone., 
Experiments by Brown et al .. (8) indicated that the 
development of carrageenin-induced edema '"'as significantly 
delayed by mid"·spinal ·transection and that morpfl:ine an(l 
other centrally-acting narcotics primarily inhibited the 
early stages of edema formation" The results of CUI' 
time-course study of carrageenin-induced ed.ema (Fig .. 5) 
did not indicate a biphasic pattern similar to that 
reported. by Vinegar (106).. Our curve vras v-ery similar 
to that clocumented by Van Arman (105)., · Vinegar (106) 
and \vinte1.~ (63) utilized. a 0.,05 ml injection of a 1% 
aqueous eat•rre.geenin solution 9 v1hile Va:o. Arman and the 
present author used a 0.,1 ml injection., This may explain 
the differences obtainea... Irrespective of whether or not 
the development of carrageenin-edema is biphasic, ·there 
"t<ras signif-ie-a-nt-eEtema-i'0Pmat-i-0n-a-s-ea~l-y-a-s-0ne-ha-l--:f:'-heux'-
after subp1antar injection., It is gc3neral1y agreed that 
this early edema formation is more susceptible to the 
effects of autonomic stimulation and autonomically acting 
drugs .. 
The effects of the benzoquinolizine derivatives 
(Tables XVII-XX) showed that tetrabenazine, RO '+-1284 and 
RO 1-9.56Lf. strongly inhibited the early phase of edema 
~ 
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.formation and hacl muc.h less effect on the latter stage~ 
This couJ.<l indicate central or peripheral involvement 
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with the autonomic responses to the . carrageenin in;jec:ciono 
As the FJarly phase of this inflammation is rather insensi-
tive to corticosteroids (107), it is unlikely that the 
benzoquinolizine-ind.uced release of endogenous steroids 
by tetrabenazine and RO 4~1284· is responsible for this 
inhibition.. IVJoreover, the (lecrease in edema fOJ:•mation at 
+ 3 h is probably not due to steroid release since RO 1-956/.J. 
\oJas activ(~ at inhibiting this latter phase and this com-~ 
pound showed little evidence of pituitary·~adrena1 stimulation., 
The a.11ti···inflammatory studies '\!lOre \'lel1 correlatea_ :for tetra-
benazine, RO 'l~l28'+ and. RO 1-9564·.. Benzquinam:i.de appeared . 
. 
to bo relatively ineffective at inhibiting the latter stage 
of carra.geen.in-induced edema"' RO 1-9564 was the only com-
pound in the series that did not proc1uce gross sedation or 
autonomic involvement at these doses~ 
Cryogenine had a more extensive inhibiting effect 
upon the latter phase of edema formationo This pattern 
of inhibition was similar to that caused by the classical 
anti-inflammatory agents.. In arlrenalectornizHd rats, 
cryogenine lost i·ts ability 'to inhibit the early stage and 
the :i.nhibi tion of the late stage was reduced by over 5096. 
This dimun:i.tion of effect upon the late stage indicated 
that part of the ant·i-inflammatory activity of cryogenine 
may be due to stimulation of the pituitary-adrenal axise 
This viTas in agreement with the data obtained in the cotton 
~ ... 
f•,•' 
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pellet granuloma. st·udies. 
In, regard to the cletermination of the involvemE::nt 
of the· pituitary-adrenal axis in the mechanism of action 
of an anti-inflammatory compound -- it should be mentioned 
that a loss or dimunition of activity after adrenalectomy 
is not conclusive evidence for this participation.. Adrenal 
extirpation removes the influence of the adrenal. medulla 
(as w·ell as the cortex) upon the inflammatory process.. The 
circulatory ana. metabolic effects of epinephrine, mobilized 
from the adrenal medulla 9 cannot be excluded dur·ing this 
type of experiment.. 'I'he probable, role of the involvement 
of the pituitary-adrenal axis as the anti·~inf'lammator;y 
mechanism for the benzoquinolizine d.erivatives has already 
been discussed. here.. The evid.Emce concerning its involve-
ment for cryogenine is less clearo The reduction of 
, cryogenine's anti-inflammatory activity after adrenalectomy 
could be due to the loss of the adrena.l meclulla as well as 
the cortex. Th~ apparent stimulation of the pituitary-
adrenal axis could be a side effect and not the mode of 
action for this compound.. Selective exper•iments involving . 
hypophysectomized ancl. adrena.l demedullatec1 animals could 
positively resolve this question. The fact that steroid 
release probably does occur with cryogenine at anti-· 
inflammatory doses in animals, would merit close observa-
tion in the event of clinical testing but this factor 
\'lOUld not negate its possible utility as a clinically use-
ful anti-inflammatory agent. Aspirin, the most widely usecl. 
F!-
g_ 
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anti··-inflammat:,ory drug, also stimulates cor-f:icosteroid 
. . . 
release under similar circumstances .. 
To date, the hypothesis of Spector and \rlilloughby 
(18,22) that catecholamines are enclogenous anti-inflammatory 
agents is highly <1ebated.. Some evidence supporting this 
hypothesi:::.; was presented i11. the introduc.tion.. Recent evi-
dence by- other in·vestigato:r·s has shovm that. epinephrine 
is capable of suppressing passive cutaneous anaphylactic 
reactions in rats ana. that this phenomena seemed to be 
associated \vith beJ;a-··aa.renergic stimulation (108)., Riesterer 
and Jacques (109) demonstrated that low doses of beta-~ 
adrenergic blocking agents vmre capable of diminishing o:r 
abolishing the anti.exuc1ative effects of aminopyrine, 
.~t~~, phe11y~Lbt1t;p_ 2'~011e, sal.~icyl .. ~~rbes 8.11<:1 h.:yClrocortisorle" Tc.,lon~ 
ancl. Bonar1era (110) have reported that epinephrine-induced. 
inhibition of increased vascular permeability can be 
decreasecl by ~blocking agents. In summary, drugs which 
reduce the uptake or destruction of catecholamines are 
thought to inhibit inflammation by the increase of free 
catecholamines at the inflammatory site -- these catecho-
lamines would be capable o.f initiating bet~-adrenergic 
stimulation., 
Tetrabenazine (92,97) is capable of diminishing 
the uptake of peripheral amines. If this is also true for 
the other benzoquinolizine derivatives (as it is for 
reserpine and chlorpromazine), the anti-inflammatory mecha-
nism for many of the drugs used in the pre~ent study might 
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be similar to that of the tricyclic antidepressants., It 
would be of interest to determj:ne the turnover rate of "-
ca:techolamines directly at an inflammatory site and to 
evaluate the effects of drugs that c1ecrease amine uptake 
and influenc(.~ catecholamine turnover., 
--------- ----------- ---
CONCLUSIONS 
It has become apparent in recent years that many 
centrally active agents possess potential anti-inflammatory 
capabilities.. The central or peripheral mechanisms of 
ac·Gion, fo;:- ·t;hese agents 11a-ve not; bee11 clel:Lr: .. eated. r1or ha~1 
thei:t." clinical efficacy been established or refuted.~ The 
centra11y active drugs, cryogeni.n(~ ana. tetrabenazine (a 
benzoquinolizine derivative) t previously· have been shovm 
in thifl laboratory to inhibit; certain models of incluced 
inflHmmation, The present study in X'at:s ve:rified.. t}le 8.nt:1-
inflammatory p:eopert:i.es of cryogenine and established that 
a. struc·i;u.ral1;y related series of benzoquinolizine cleriva-
tives possessed the capabilit,y o:t' inhibit-ing both exua.ative 
(carrageen:i.n~·:induced pedal edema) and proliferatiil'e (cotton 
pellet granuloma) models of ind.uced inflammation when 
adm:i.nist(:lred orally .. 
~ehe anti-·inflarnmatory activity of those benzo-
quinolizine df~rivatives v1ith resex•pine-J.ike activity 
(tetrabenazine~ RO 4-1284, and benzquinamide) was associated 
\'lith but apparently not depenclent upon stimulation of the 
pituitary-·ad.renal axis. There did not appear to be any 
correlation of sedation, depletion of brain monoam:Lnes, 
or analgesia \'lith the anti-inflammatory potency of these 
compounds.. The extreme sedation and au-tonomic side-effects 
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manifested at effc~ct:i.ve anti-inflammatory <1osage levels 
dimin:Lshe.s their possible u:t:i.lity in clinicaJ. practice .. 
A second type of benzoquinolizin.E-) derivative 
(RO 1-9564·) also demonstrated potent anti--inflammatory 
activity_.,. However-~ this activity was not accompanied 
by ctepletion of brain amines, sedation or aui.~ononliG mani~ 
festat-;ionn and there \>Jas little to no apparent stimulation 
of the pituitary~adrenal axis at anti~inflammatory dosage 
levels. The lack of obvious side·-effects for this secona. 
t;y-pe of benzoquinolizine suggests that they may bE-) clini--
cally useful anti-inflammatory drugs either alone or in 
combination \·Ji th more established agents .. 
The anti-inflammatory ac:t;i vity of cryogenine vras 
not associatr::d with depietion of' Nhole b:r·ain OJ.." heart mono·-· 
amines.. At anti-inflammator~.r dosage levels~ there "Vms an 
apparent f~timulation of the pi tuitary~adren.al axis but this 
ma;y· have been a side-effect rather than the mode of action 
for this compound.. Aclrenal stimulation does not preclude 
its u:t:LJ.i t;r in clinical practice, since aspirin, the most 
clinically reliable and. wi0.ely used anti-·inflammatory 
compound to date, also has been reported to cause ad.renal 
stimulation at high dosage levels., 
g_ 
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· APPENDTX A 
SEROTONTN AND NOHEPINEPI-ffiiNE ASSAY IN TISSUES (57) 
The following nn.alytic.al techniques were .follo-v,rE~d ~ 
I. .H(~aE.~~-~-~~..:~t a:E-~'!:3.~ 
A.. ]~fu__.§£1-t ::~tupat££~~?:~9~2}· J:.~ ted. -'.~.:h!l?· 0 .. Q;.Q.r. 
HCl -- make up fresh weekly., Stir vigorously (large mag~ 
netic ntirrer) 2 liters of J:i'ish(:)r A-399 Cf~rtii'ied Reagent 
!!,-butanol (DuOH) \vii;h 800 ml of 0 •. 01N HC1 for o,.rj h.,. Suc.k 
out aqueous phase and sti~ ... butanol vigorously vrith ca .. 
230 g of NaCl for 0~5 h~ A . . sp:t.rw:: e o.ff the aqueous phase 
gl~u;1:.~-st:oppered (GS) bottle containing fresh NaCl.. Ter:;t 
thE! BuOH by checking fluorescence of serot:onin (5-H~~) 
stand.ards (in duplicate) prepared with pu.re O .. OHT HCl and 
\'T:i.th BuOH (20 ml)·-heptane (35 ml) saturated o .. on:r HCl (3 ·m1) 
ai ... tt")r 0 .. ~5 h and 1 h~ Store BuOH in the <1ark., 
B.., Purification of BuOH -- For J!'isher BuOH, I·*a is 
sufficient.. If the 5-IU' standards fall rapidly in the 
stability test, the BuOH should be purified as follows. 
Stir vigorously 2 liters of BuOH + 400 ml of 2N NaOH for 
0.5 h.. Aspirate off the aqueous phase and wash BuOH 
(Beparatory funnel) with 200 ml of \tm.ter (3 times)" Stir 
BuOH layer with 400 rnl of O.OlN HCl fOl" 0 .. 5 ho Aspirate 
ou-t; aqueous phase and. allow to stand overnj:ght. Dc~can.t BuOII 
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into 2 liter G-8 bottle containing fresh NaCl.., ·Test BuOH 
as in I-a.. Store BuOH in the dark; .. 
10E3 
C., Salt --· Granular~ Fisher S-271 Certified Heagent 
Sodium Chloride~ 
Do He£t~o~- -- Normal, Fisher H-34-0 Spectranalyzed ... 
E. Hcl· -- ~Phis term always refers to O<JOlN HCl .. 
Dilute 2.,0 rnl of concentrated HCl (J .. T .. Baker 9535) Heagent 
to 2.J~l liters 'l.vith distilled water .. 
F" !aOH -- Stock solution (5095 \v/lv): add 2 liters of 
water to 2 kg of NaOH (J .. T .. Baker 3722) in a nalgene beaker 
and. stir magnetically until NaOH is dissolvea... Filter 
(sintered·-glass) and store in plastic bottles,, J.i'or d:ilute 
NaOH make up as follows: 
1J:if ~ diltrce 84 g of stock solution to 1 liter w:i.t;h \·rat: e-r• ... 
2N: ct:i.l ute 168 0' o.f stock solution to 1 -~ . ~ wrt;n 'l.T,..,o.l-n•"f"t <_) w_lt;er •• , ~-A. 't \.,.- .~' ~ 
5N: dilute l~20 g of stock solution to 1 liter with water ... 
G., podiu~ce!_ate; _ _(_~r·'I) -- Dissolve 27 .. 2 g of NaOAc" 3H20 
(J., T. Baker 3L~60) in \•later and dilute to 100 ml in a volu-
metric flask .. 
H.. Acetic Acid {2H) --- Dilute 11 .. 45 rnl of glacial 
acetic acid (tT .. T .. Baker 9507) to 100 m1 in a volumetric 
flask '\vith water .. 
I.. Acetate buff~r (2~1, P!L2l -- Add one volume of 
21~1 HO.Ac t-o two volumes of 2I'1 NaOAc (check pH).. Refrigerate 
for storage. Haximum amount to make up: ££3...• 150 ml., 
J·., ~hiosulfate _,_(0.05N) 
H'">O (J •. T .. Baker 3946) in 100 ml of \'mter (note l)e 
c.. 
Ko Iodi~~ (~!]Nl -- Dissolve lo27 g of iodine (J. T. 
ci_ 
-
~· 
-~ 
--
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Bake:r.· 2208) in 100 ml of absolute ethanol., Refrigerate 
(note 1). 
!1. Ascorbic aeid (1%) -- Dissolv·e 1 g of ascorbic 
acid ( J.. T.. Baker B581) in 100 ml of \·rater.. r1ake fro sh 
on the day of assay .. 
M.. Alkaline ascorbate solution ···~ Mix 1 volume of 
Sha.lm well., 
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N.. NE standard -- Stock solution (100 mcg/m.l in Hen): 
,~, .... ~ . 
dissolve 19 .. 9 ~ mg of 1-arteJ."enol bitartrate monohydrate 
(Winthrop labs.) and make up to 100 ml with HCl., Re:frirserate 
for storageo \Vorking standarcls contain 1 .. 0, 2 .. 0, and 4 .. 0 
mcg/ml .. 
HCl): dissolve 23.,0 mg of serotonin creatinine sulfate mono-~ 
hydrate (Nutritional Biochemicals Inc .. ) to 100 ml 't'lith HCl., 
Refrigerate fOl.' storage., Working. standards contain 2 .. 0, 
4.0, and 6.,0 mcg/ml .. 
II., General assay . Fr:.O_<?~a.u:r:~ · 
A. Number consecutively a series of 120 ml bottles<~ 
that are either glass-stoppered or have screw caps lined 
\'lith aluminum foil, to correspond to samples and 6 extra 
bottles corresponding to pooled tissue sample (~1P), spiked 
tissue samples (TSl, TS2,·and TS3), reagent blank and 
standard .. 
1. To sample and TP bottles add 0 .. 5 ml HCl, 
l~ g of Na.Cl and 30 ml of BuOH .. 
110 
2., To TSl a.nd TS 2 bot·tles add l.J, g of NaCl 
and 30 ml of BuOH., , 
3. Blank - see step II-K~ 
4., Standard - see step II-L. 
B" Homogenize weighed f.£2~1! tissue~ (weigh rapidly -
tiss~~-P!.._U_E;_:t; not Ciefr_£>st in HCl) 
1 .. Brain - use 1 g of brain ·+ 2 ml of HCl .. 
Use 1 rat brain per determination., 
2 .. Heart - use 1 g of heart· .+ 5 ml of HCl .. 
Use 1 rat heart per determination (see note E)., 
Other tissues dependent on 5~~nr.r)J'TE content .. 
C .. Pipet (blo'Vr-out) 2.,5 rnl of. homogenate into each 
sample bottle from Eltep II-A~ 
D., Combine res:Ld1.1.al sample homogenates a.no. rehomo-
genize for mixing.. Pipet 2 .. 5 ml aliquote into ~l'P, TSl, TS2, 
and ~rs3 bottles .. 
E., To TSl bottle, add 0 .. 25 ml of 5-H~I' (2 mcg/ml) 
+ 0 .. 25 ml of NE (1 mcg/inl)., To TS2 bottle, add 0.,25 ml of 
5-HT (4 mcg/ml) + NE (2 mcg/ml).. To 1:1:83 bottle add 0 .. 25 ml 
of 5~HT ( 6 mcg/mg) + NK ( 4 mcg/ml) .. 
F. Shake 065 h on bottle shaker .. 
G.. Centrifuge bottles at 2500 RPIVI for 3 to 5 min. 
H.. Pipet (via. 50 ml syringe attached to a 20 ml 
. -
v-olumetric pipet) 20 ml of the HuOH layer into clean 120 ml 
bottles containing 35 ml of heptane + 3 ml of HCJ.. Shake 
for 3 min. 
I.. Centrifuge bottle from. step H .. 
'1 
;c; 
J tl> Pipet into test tubes (16 x 150 mm): 
+" 1 ml of aqueous layer for 5~HT assay 
(volumetric pipet)~ 
2 .. · 1 e. 5 m1 of aqueous 1a;y·er for NE assay 
(2 m1 blm.,r--out) See note D. 
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K., Blank: 8hake 3 ml of HCl + ~20 ml of BuOH + 35 ml 
of heptane for 3 min.. Centrifuge and pipet out 1 ml (5-Wl') 
and. 1 .. 5 ml (NE) aliquots for assay .. 
L.. Standards: shake 3 rnl o:r HC1 as in step K., 
Centrifuge and pipet out 2 .. 5 ml of HGl layer~ and add 
0.,.25 ml of 5-HT ('+ mcg/ml) + 0 ... 25 ml of NE (2 mcg/ml),. 
Pipet out 1 ml (5-HT) and 1 .. 5 m1 (NE) aliquots for assay .. 
A.. Acl.d. 0 .. 3 m1 of concentratecl HC1 to each 1 ml 
aliquot (steps II-JIG~), Hix well .. 
B.. Transfer (disposable pipet) to cuvet·ce and. read 
96 transmission in the spectrophotofluorometer .. 
1., \vave lengths -- 300 millimicrons (activation) 
550 millimicrons (fluorescent).. VJave lengths 
should. be checked each d.ay for slight spectral 
shifts .. 
2... lp-·21 or lp-28 phototubes (see note) .. 
A. To 1 .. 5 ml aliquot (steps II-JIITs) add 0 .. 5 ml of 
pH 5 acetate buffer. Hix well. 
B. Add 0 .. 05 ml of iodine solution; mix well, let 
-
~-
---~·- --------
stand 6 min .. 
c. Add 0.1 ml of thiosulfate solution; mix \'!ell 
(iodine color will disappear) .. 
D. Immediately ad<l 0 .. 5 ml of fresh alkaline ascor-
bate solution., Shake well. 
EQ Irradiate tubes for 20 min under double fluorescent 
\oJhite lamps (General :rnect:r:-:i.c Co .. 20 \•7at1.; )., 
Ji'.. Transfer ca.. 1 ml to cuvette ana. read 96 trans·-
mission., 
1.., Wa"tre lengths ca-. 400 millimicJ:•ons 
(activation) 510 millimicrons 
(fluorescent) .. 
Y.. Calculation of amine 1E~vels 
.. , ... ...;.  ..-~~..,.~------... ---· -- .. -·~---
A., Determine "fluor~~scence units/meg of spiked 5-~m:nt 
by (TSl-'J~P + TS2-TP + TS3-TP)/3 .. 
B. Determine "f'luorescence units/meg of spiked NE" 
by (TS~TP + TS2-TP + TS3-TP)/1.?5., 
c. Amine level (mcg/g of \'let tissue) = 
_{.~~E!J?)-.~:.b1a .. ~~)-~(E~om_og_en~te v<:>l~~ of tiss.ue) __ _,_ 
"{T.tu_o:r;.escent U7ln1crogram of sp:i:K'eer am1.ne )"\1i0mogenate sample 
VOlUme) 
D. Determine mean level in each set and calculate 
standard errors if desired., 
E.., Recovery (%) = 1 .. 5 (~'Sl-TP) (100) 
-- sliar1aa·ra-'61arik-
for 5-HT, recovery = 80-100% 
for N1~ s :r·ecov-ery = 50-65%. 
VI.,. Notes 
A. Dilute 1 .. 00 ml aliquot of' iodine \'lith 10 ml of 
ethanol and titrate with thiosulfate solution; 1 .. 00 ml of 
iodine must be _j_ust decolor:ized with 1.,85-1 .. 90 ml of 
thiosulfate .. 
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B.. fJieter multiplier/sensitivity settings will depend 
on hm,_r sen::.dtive photomultiplier tube is .. 
C., Benzoquinolizines interfere \llith NE assay.,. Pro·-
cedure is moc1i.fied to remove d.rug from tissue •. 
1.,. Shake 2.,5 ml of homogenate and. either 0.,5 ml 
of HCl or (0 .. 25 ml of 5-HT + 0.25 ml of NE) 
wi·!;h 20 ml of reagent grade CHC1'A for 5 min~ 
:.J 
cen·!;ri:fuge,. and aspirc:d; e out ~fv:..~-}.:.'l the 
chloroform layer \>rith a. syringe n.eecne ancl 
v·acuum., Repeat b:d.ce.. Add 30 ml of BuOH ancl 
L~ g of NaCl and proceed to step II-I!'.. 
2 c· Pre-extract 3 ml of HCl with two 20 ml volumes 
of chloroform anc1 proceed with steps II-K and 
II-L for the blank and standard respectively., 
D. If d.opamine (DA) is also assayed, take only 0 .. 9, ml 
aliquots for NE .. . ~f.lhen use in step IV: 
pH 5 buffer 0 .. 30 ml 
iod_i.ne 0.03 ml 
thiosulfate 0 .. 06 ml 
ascorbate 0.,30 ml 
E. Hearts are frozen in liquid nitrogen and pulverized 
in a tablet die before homogenization (58) .. 
:B'. If' lp-28 phototube is used a filter must be inserted 
to remove second ord.er scattering from the 295 millimicron 
activation light .. 
-- ---- - -- ---
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